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According to the World Health Organization, breast cancer is the most common cancer among
women worldwide, claiming lives of hundreds of thousands of women each year. Mammography,
ultrasound (US) and magnetic resonance imaging (MRI) are widely used to detect and diagnose
breast lesions and each of them have some disadvantages which motivates researchers to find a
new and high sensitive imaging method. Diffuse optical tomography (DOT) is a noninvasive
functional imaging modality that utilizes near-infrared (NIR) light to probe tissue optical
properties. Minimal light absorption in the NIR spectrum allows for several centimeters of light
penetration in soft tissue. NIR is sensitive to hemoglobin which is directly related to tumor
angiogenesis. If multiple wavelengths are used, it can probe tumor oxygen saturation. However,
DOT has drawbacks on location uncertainty and low light quantification accuracy due to tissue
scattering of NIR light. Ultrasound (US)-guided Diffuse Optical Tomography has overcome these
problems.
The overall objective of my research is to move US-guided DOT one step closer from a research
imaging modality to a commercial prototype for future wide use in clinics. To achieve this goal, I
have overcome several challenges in both imaging hardware and software. In this Dissertation, I
will discuss the progress we have made on development of two generations of US-guided DOT
systems along with the software improvements. The developed systems have been improved in
terms of robustness, stability, clinical safety and standards and user friendliness. In terms of
software and algorithm development, automated methods for data selection, outlier removal and
reference and perturbation filtering are presented. These methods have improved the robustness of
the technique and increased speed of image formation by eliminating the need for an expert to
perform data preprocessing and data selection. Phantom and clinical experimental results will be
demonstrated to evaluate the performance of the developed systems and algorithms.
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1. Introduction to Breast
Imaging

1.1. Introduction
Medical imaging is a wide expanding field of development and research. Several methods and
modalities for medical imaging have been developed during last century and they have found wide
application in disease screening, diagnosis, and treatment monitoring. While each of the currently
used conventional imaging has their strength and drawbacks, the urge to develop a new imaging
technique, which could address current needs in medical application to improve human health, is
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being felt more than ever. One of the promising ideas for next-generation medical imaging devices
is optical imaging. While several methods of optical imaging with different wavelength sub-bands
are currently under investigation, I am going to focus on the use of near infra-red light in optical
imaging. The infrared light has several interesting characteristics such as good depth of penetration
inside the tissue and sensitivity to hemoglobin. In this dissertation, I will specifically talk about
near infra-red diffuse optical tomography method and the steps I took to move this modality one
step closer to use widely in the clinical setting for breast cancer detection.
The dissertation is structured as below:
Chapter 1 gives a brief introduction to the background of the medical imaging and breast
cancer.
Chapter 2 is discussing the principles of near infra-red diffuse optical tomography and its
expansion to ultrasound-guided diffuse optical tomography.
Chapter 3 is focused on the development of the third generation of the ultrasound-guided
diffuse optical tomography system and the results of clinical studies which have been done with
that system.
Chapter 4 is along the path of chapter 3 and discuss the development of the fourth
generation of Ultrasound-guided DOT system. In that chapter, we’ll discuss the results of phantom
experiments which have been done with this system.
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In chapter 5 we’ll study the effect of reference heterogeneity on the reconstructed DOT
absorption map and introduce a smoothing method to reduce the effect of the reference
heterogeneity in the reconstructed absorption map.
Chapter 6 is dedicated to the algorithm developments for improving the robustness of
diffuse optical tomography technique for breast cancer detection. This algorithm specifically
focuses on using multiple references and a perturbation filtering method to eliminate measurement
outliers. This algorithm makes the process of data preprocessing automated by forming a robust
reference measurement to eliminate the need for an expert user in data processing and improve the
accuracy of US-guided DOT.
Finally, in chapter 7, we will summarize the first 6 chapters and make a conclusion about
the progress we have made and provide ideas for the next step of system and algorithm
development.
With this short introduction, we will continue to review the basic concepts which are going to
be used in this Ph.D. Dissertation.

1.2. History of Medical Imaging
Wilhelm Röntgen, a physics professor discovered the x-rays in 1895 and it has been the start point
of medical imaging. Different density of tissue results in different absorption of the X-ray passing
through the tissue and results in a different number of x-ray photons reaching the film or camera
detector on the other side of the tissue. This concept of utilizing different absorption of the X-Ray
to map the density of the underlying tissue was a great breakthrough at the time and it
4

revolutionized the field of medical science and diagnosis [1]. Although the x-ray was a great
breakthrough in the field of diagnostic sciences, scientists were not aware of the dangers of
ionizing radiation of x-ray. Besides that, while x-ray has a great ability to differentiate soft tissue
from the bones and hard objects, it lacked sensitivity to distinguish different soft tissues.
The second breakthrough in medical imaging happened in 1960’s when the principles of
ultrasonic beams have been utilized for medical imaging and the simple 2D ultrasound imaging
devices were developed. Since then, this technology was expanded and several devices with
multiple applications including, Sonographer, Echocardiography, Doppler blood flow
measurements, and focused ultrasound have been developed. Besides all the improvements, the
concept of ultrasound remained fixed. The ultrasound transducer transmits high-frequency
ultrasound waves into a body and the pulses or waves penetrate the body and bounce back from
the tissue. The bounced back ultrasound waves are detected by the transducer and convert to
electrical signals. The time delay of each detected ultrasound pulse represents the path this pulse
has traveled inside the tissue and the intensity of it represent the mechanical properties of the tissue
it passed through and bounced back from. This information is used to form an image of the
mechanical properties of the tissue. Since ultrasound had no known adverse effect on the patients,
it is one of the safest and popular imaging technique [2].
Computed tomography was invented in 1970’s. This technique uses computer-processed
X-rays in different angles to form tomographic slices of the body. As it could provide tomographic
slices, it improved the insight into the pathogenesis of the body and diagnosis. The early generation
of X-ray imaging was slow due to the computational cost of this technique, but now a day, by
developments in computer processing a CT scanner can reconstruct a tomographic image almost
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instantly [3]. The two contributing inventors of this technology have received a Nobel Prize in
medicine.
At the same time when the computed tomography was invented, Raymond Damadian
discovered the difference of the nuclear magnetic relaxation times between the different tissues.
As it was a promising discovery, several researchers all around the world worked around 20 years
to develop this concept into Magnetic Resonance Imaging (MRI) technology. MRI sends strong
magnetic waves through the body which causes the alignment of the protons. While these protons
move back into their original positions, they radiate waves which are detected by the detector.
These different radiations of particles inside the body are then used to form an image. Currently,
MRI is widely used for diagnostic applications by providing very good differentiation between
different soft tissues [4].

1.3. Breast Cancer
Breast, lung, and colorectum cancers are the three most commonly diagnosed cancers, representing
one-half of all cancer cases among women. Breast cancer alone is expected to account for 29% all
new cancer diagnoses in women in 2017. In average, one out of 8 American women will develop
breast cancer over the course of their lifetime. Based on the statistics from American cancer
society, right now there are around 2.8 million women with a history of breast cancer in the united
states. This number includes women currently being treated and women who have completed
receiving treatment. It has been estimated that in united states in 2017, 255,180 new cases of
invasive breast cancer along with 63,410 new cases of non-invasive breast cancer will be detected.
6

Despite the decrease in death rates for breast cancer since 1989, it is estimated that unfortunately
about 40,610 women will die from breast cancer in 2017 [12,13].
In breast cancer cells in the breast start to grow out of control and form a tumor. If the tumor cells
have the potential to invade surrounding tissues or spread to distant areas of the body the tumor is
called Malignant. Here we should note that most of the breast lesions do not invade surrounding
tissue or spread to the other part of the body. These kinds of lesions are benign lesions.
Although benign lesions are abnormally grown inside the breast, unlike the malignant lesions they
are not life-threatening for the patient as they are not invasive.

Figure 1.1. Normal breast tissue (ref. National cancer institute, [5,6])
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1.4. Breast Cancer Diagnosis and
Treatment Monitoring
Different imaging methods have been used for both detection and treatment monitoring phase of
breast cancer. Conventional imaging methods such as mammography, ultrasound imaging (US),
and magnetic resonance imaging (MRI), are the most commonly used methods to detect and
diagnose breast cancer. Mammography as the most clinically used imaging modality for breast
cancer diagnosis has relatively low sensitivity in early cancer diagnosis and weak sensitivity in
women with dense breasts [14]. ultrasound demonstrates robust results in detecting breast cancer
with comparable rate to mammography, but it still lacks sensitivity and specificity which results
in several false positive cases [15]. MRI, on the other hand, shows a significantly higher sensitivity
in breast cancer detection and diagnosis compared to US and mammogram, but the high costs of
MRI and relatively low cancer detection rate in the general screening population limits its
applicability as a screening and monitoring tool in several situations [14]. In the treatment phase
of breast cancer, different modalities have been used to monitor the patient response to the
neoadjuvant chemotherapy, while a method that can provide accurate results at early stages of
treatment is yet to be found. On one hand, US and mammography, are two highly used methods
to monitor the response of patients to neoadjuvant chemotherapy and they just show moderate
sensitivity in the assessment of tumor response. On the other hand, dynamic contrast-enhanced
MRI and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed
tomography (PET/CT) can predict the presence of residual tumor after completion of each NAC
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which could decrease the patient additional exposure to ineffective and toxic treatments [15-17].
Although these methods have shown the ability in early identification of patients not responding
to neoadjuvant chemotherapy, their equipment is bulky and expensive, and they require the
injection of contrast agents which prevent them from being used repeatedly for monitoring patients
during treatment.
Optical imaging using near infra-red light has shown promising results in detection and
diagnosis of breast cancer and this technique will be discussed in chapter two with more details.

9
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2. Ultrasound-guided Diffuse
Optical Tomography

11

2.1. Diffuse Optical Tomography
In last decades, the application of near infra-red (NIR) light for imaging has been under intense
investigation. NIR diffuse optical tomography (DOT) is a noninvasive imaging technique that uses
near infra-red light to assess optical properties of tissue. Because of the minimal light absorption
of water at the near infra-red wavelength range (∼700 to 900 nm), the light will penetrate
sufficiently in tissue to acquire tomographic images [1-4]. Besides the low absorption of water at
12

near infra-red, this wavelength range is also sensitive to oxygenated and deoxygenated hemoglobin
(HbO2 and Hb) [5,6]. Oxygenated and deoxygenated hemoglobin are two important chromophores
found in the cancer lesions, and are related to tumor angiogenesis and cell activity. This sensitivity
to oxy and deoxyhemoglobin results in several important applications for this technology such as
brain activity monitoring and cancer detection. This sensitivity also resulted in promising results
in assessing breast cancer. Besides that, DOT also has demonstrated great potential in the
assessment of tumor vasculature response to neoadjuvant chemotherapy. DOT systems are
portable, require no contrast agents, and have a low cost which makes them an ideal alternative for
currently used modality for breast cancer diagnosis and monitoring in clinical settings. Besides
aforementioned benefits, DOT can be used as a complimentary breast imaging method along with,
ultrasound, X-ray mammography, and magnetic resonance imaging (MRI) in the diagnosis of
breast cancer as well as treatment monitoring. Several research groups are investigating different
techniques of diffuse optical tomography. In general, these researchers can be divided into 3
different groups, as time domain, frequency domain, and continuous wave DOT. Some groups,
including our group, combine DOT imaging modality with another modality, such as ultrasound
or MRI. We focused on frequency domain diffuse optical tomography systems and we combined
it with ultrasound imaging method. We have studied the feasibility of using US-guided NIR
imaging technique for detecting breast cancer as well as monitoring patients who were undergoing
Neo-adjuvant chemotherapy [7].
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2.2. Ultrasound-guided DOT
Ultrasound-guided diffuse optical tomography (US-guided DOT) uses ultrasound as a guidance to
localize the lesion and improve the tissue illumination and reconstruction results. In our approach
of US-guided DOT, we acquire 3 different measurements for each experiment. The very first
measurements are from a known intralipid solution which will be used to calibrate the rest of the
measurements from the patients. We then use ultrasound to localize the lesion and acquire multiple
sets of measurements from the lesion site. Next, we move the probe to the contralateral breast to
acquire multiple reference measurements. Then these measurements are used to reconstruct image
as is described here.
First, the Intralipid datasets are loaded to calculate the system parameters for calibration,
then the contralateral normal breast is measured, and data processed to estimate background tissue
optical properties. These properties are used to compute a weight matrix for image reconstruction.
The perturbation or scattered field is calculated as the difference between the reference data and
the lesion data. Finally, by solving the inverse problem, the absorption distribution inside the
medium can be estimated.
Born approximation is used to relate the scattered field (Usc) measured at the probe surface
to absorption variations in each volume element within the sample. In the Born approximation, the
scattered field measured at source (s) and detector (d) is related to the weight W and the absorption
change,  a , inside the medium. By digitizing the imaging volume into N voxels, the matrix form
of image reconstruction is given by

U sd M 1  W M N [ a ]N1
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(1)

where M is the total number of source-detector pairs, and W is the weight matrix, which describes
the distribution of diffuse wave in the homogenous medium and characterizes the measurement
sensitivity to different voxels inside the medium. To solve the unknown absorption distribution,
the inverse problem is formulated as an optimization problem as:

, where

is the Euclidean norm. The conjugate gradient method is used to solve the inverse problem.
Because the total number of source-detector pairs (M) on the probe is much smaller than the total
number of voxels in the medium, the inverse problem is underdetermined and ill-posed. However,
ultrasound is excellent in providing the information about the target depth and approximate size of
target. We have integrated the target information from ultrasound and developed the dual-mesh
imaging reconstruction algorithm. Briefly, the entire tissue volume is segmented based on initial
co-registered ultrasound measurements into a lesion region L and a background region B. The
image reconstruction matrix is given as:

U sd M 1  WL ,WB M N [M L , M B ]T N1

(2)

where WL and WB are weight matrices for lesion and background regions, respectively, and [ML]
= [∫1L Δµa (r′) d3 r′, ...... ∫NL Δµa (r′) d3 r′ and [MB] = [∫1B Δµa (r′) d3 r′, ...... ∫NB Δµa (r′) d3 r′) are
total absorption distributions of lesion and background regions, respectively. The absorption
distributions can be obtained by dividing the total absorption with the voxel sizes of lesion and
background, respectively.
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2.3. DOT for Neoadjuvant Chemotherapy
In the past decade, optical tomography and optical spectroscopy using near-infrared (NIR) diffused
light has demonstrated great potential in the assessment of tumor vasculature and oxygen
consumption responses to NAC [8-20]. The NIR technique utilizes intrinsic hemoglobin contrast,
which is directly related to tumor angiogenesis, a key process required for tumor growth and
metastasis. When multiple wavelengths are used, the optical absorptions at those wavelengths can
be measured, and the proportions of oxygenated hemoglobin (oxyHb) and deoxygenated
hemoglobin (deoxy-Hb) can be calculated, which are correlated with tumor oxygen metabolism
and treatment resistance.
Optical systems are low cost and safe with no ionizing radiation and are ideally suited for
repeated use at clinical settings. Recently, significant progress has been made on early prediction
of NAC using Optical spectroscopy or tomography. In a study using NIR spectroscopy, 11 patients
were monitored pretreatment and within one week of initial treatment [8]. DeoxyHb decreased
within the first week in pathologically confirmed responders, whereas no significant change was
found in non-responders. In addition, the measured total hemoglobin (tHb) decreased in all
responders. Another study of 23 patients reported by the same group found a statistically
significant increase, or flare, in oxyHb in responders on day 1, in contrast with a lack of flare or
decrease in oxyHb noted on day 1 in non-responders [13]. An additional study reported by Ueda
et al has shown that the pretreatment or baseline tumor oxygen saturation SO2 = oxyHb/tHb×100
correlates with the pathological complete response for patients undergoing NAC [16]. Recently, a
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study reported by Jiang et al have shown that pretreatment tHb measured by Diffuse Optical
Spectroscopic Tomographic imaging predicts breast tumor response to NAC [19].
We previously have developed a dual-modality approach by using the co-registered US to
guide light illumination, reception and also image reconstruction [10,14, 20, 21]. This approach
overcomes the problem of poor lesion localization of light due to optical scattering and improves
reconstruction accuracy of lesions by using a priori lesion depth and size information obtained
from US images.

Recently, a multi-year study using US-guided Optical Tomography has

completed. A total of 32 patients who were undergoing NAC were assessed pretreatment, at the
end of every treatment cycle, and before surgery [15]. The significant findings from this group of
patients are: 1) pretreatment tumor hemoglobin content (tHb, oxy- and deoxy-hemoglobin)
predicts patient pathological response to NAC, 2) the percentage of tHb changes (%tHb)
normalized to the pretreatment level can be used to further identify responders from nonresponders at the early treatment cycles (2 to 3 weeks after the initiation of NAC), 3) combining
widely used tumor pathologic variables and receptor status with hemoglobin functional parameters
obtained before the initiation of NAC, substantially improved prediction can be achieved using a
logistic prediction model [19].
To validate these results at multiple sites, we have developed third and fourth generation
of US-guided NIR diffuse optical tomography (DOT) systems for clinical experiments. The new
systems are compact, portable and robust in clinical operation. In the next two chapters, I focus on
the development of the third and fourth generation of the US-guided NIR diffuse optical
tomography (DOT) systems. The results of the clinical studies with the third generation of the
system are presented in chapter three, and the phantom results of the fourth generation of the
system are presented in chapter four.
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3. Development of Third-gen
US-guided DOT System
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3.1. Abstract
In this chapter, I’ll describe the development of the third generation of ultrasound guided diffuse
optical tomography (US-DOT) system and then present the US-DOT system progress of utilizing
ultrasound-guided diffuse optical tomography for predicting and monitoring neoadjuvant
chemotherapy outcomes of breast cancer patients. The clinical results acquired with the developed
prototype for the first patient will be discussed in this chapter. The patients have been closely
monitored before NAC, at day 2, day 8, end of first three cycles of NAC and before surgery and
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the imaging result is given as an example to demonstrate the potential of US-guided DOT
technique and the performance of our system in clinical setting.

3.2. Introduction
Neoadjuvant chemotherapy (NAC) is increasingly used treatment to prepare patients with locally
advanced breast cancers for surgery. The patient may receive neoadjuvant chemotherapy for breast
cancer to shrink a tumor that is inoperable in its current state, so it can be surgically removed.
Neoadjuvant therapy is also used for the patients whose tumor can be removed by mastectomy, to
shrink the tumor enough to allow breast-conserving surgery. If a tumor does not respond (shrink)
or continues to grow during neoadjuvant chemotherapy, the doctor may stop treatment and try
another type of chemotherapy or perform surgery instead, depending on the stage of cancer.

The role of imaging for treated patients with neoadjuvant therapy for breast cancer is not only
to evaluate the therapeutic response in terms of tumor shrinkage but also to predict the histological
response to chemotherapy, which is correlated to survival rate. Surgery and histopathological
analysis after neoadjuvant therapy allow for an objective assessment of the accuracy of imaging
techniques in evaluating response. Different modalities have been used to differentiate between
patients who respond and who don't respond to NAC; while a method which can provide accurate
results at early stages of treatment is yet to be fully developed.
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Physical examination is providing mediocre accuracy for assessing the response of locally
advanced breast cancer to NAC treatment. It could be because of either palpation of a fibrotic and
necrotic mass which may mimic a residual tumor mass or due to the resolution of post-biopsy
phenomena such as hemorrhage and edema. Mammography and ultrasound are the most used
methods for the initial staging and the assessment of tumor response to neoadjuvant
chemotherapies. These methods are aiming the comparative measurement of the tumoral volume
and the accuracy of them highly depends on the contrast between the tumor and the surrounding
normal tissue. MRI allows morphological analysis of tumors and kinetic study of the contrast
enhancement reflecting the richness of the vascularization, which could provide early
identification of nonresponders. This method can predict the presence of residual tumor after
completion of each NAC which could decrease the patient additional exposure to ineffective and
toxic treatments. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed
tomography (PET/CT) have been reported to show good performance in excluding distant
metastases prior to neoadjuvant chemotherapy (NAC) treatment. The usage of MRI and PET/CT
are not suitable for repetitive use, because the equipment is bulky and expensive, and PET/CT
require the injection of contrast agents as well. These constraints prevent them from being used
repeatedly for monitoring patients during treatment.

Diffuse optical tomography (DOT) in the near-infrared (NIR) spectrum provides a unique
approach for functional diagnostic imaging. This imaging technique can detect endogenous
absorbers, and also determine the hemoglobin concentration and oxygen saturation. Near-infrared
diffuse optical tomography (NIR-DOT) systems are portable, low cost, non-ionizing and require
no contrast agents, which make them an ideal alternative for repeated use in clinical settings. Near-
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infrared (NIR) diffuse optical tomography also has demonstrated great potential in the assessment
of tumor vasculature response to neoadjuvant chemotherapy.

3.3. Previous Systems
In the past, we have developed two frequency domain DOT prototype systems which were used
with commercial ultrasound systems in clinical studies. The first prototype system consisted of
12 pairs of laser diodes of wavelength 780 and 830 nm and eight parallel channel photomultiplier
tube (PMT) detectors [1]. Each pair of dual-wavelength laser diodes delivered the light through
an optical coupler to a hand-held probe of 10 cm diameter and all parallel detectors received the
reflected light simultaneously via optical light guides mounted on the probe. The laser diodes
were modulated at 140MHz and the detected signals were mixed with the 140.02 MHz reference
signal and were further amplified and filtered at 20 KHz for processing. A commercial ultrasound
array transducer was located in the middle of the probe for guiding the localization of breast lesions
and image reconstruction.
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Figure.3.1. First generation of Ultrasound guided DOT system along with custom made 64 channels
ultrasound system

The second prototype system consisted of four laser didoes of wavelengths 740, 780, 808
and 830nm which were sequentially switched by 4 x 1 and 1 x 9 optical switches to 9 source
positions on the hand-held probe [2]. The detection included 10 photomultiplier tube (PMT)
detectors and associated parallel electronics. The reflected light was coupled to the detectors via
optical light guides mounted on the probe. The initial promising clinical results obtained from
these prototype systems have been reported in several publications [2-7].
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US System
NIR System

Hand-held probe

Han
Figure.3.2. Second generation of Ultrasound guided DOT system along with a commercial ultrasound system

In both prototypes, a pair of National Instrument Data Acquisition (DAQ) boards and a desk
top PC were used for data acquisition and display which has contributed to the bulkiness of the
system in clinical studies.

3.4. Third-Gen of NIR-DOT system
In our early prototypes, the two National Instrument Data Acquisition (DAQ) boards and cables
which connect DAQ boards inside a desktop PC to the NIR system have contributed to the cost
and significant bulkiness of the system because two rigid RF shielding cables have to be used to
reduce ~20KHz interference signals generated from beating of two high frequency signals from

26

source and detection systems. We have replaced the two NI DAQ boards with a custom-designed
compact on-board DAQ board which will be housed inside the detection.
The DAQ consists of two AD7609 ICs (Analog Device), one SPARTAN 3E FPGA and 2MB
SRAM. AD7609 has 8 simultaneously differential input channels with analog input range of ±10V
which is ideal to handle a larger dynamic range of diffused light signals received from near and
far source-detector pairs. The sampling speed of AD7609 is 200kHz and resolution is 18 bits. The
SPARTAN 3E FPGA features 18-bit multipliers, 72Kbits of fast dual-port block RAM, and
500MHz+ operation. It has USB 2 full-speed port for FPGA configuration and data transfers to a
lap top PC. The 2MB 16 SRAM is designed to buffer the data for one set of data acquired from
all wavelengths and all sources and detectors. Figure 3.3 illustrate the block diagram of the FPGA

EZ USB
chip

Input channels 1-8

EEPROM

based data acquisition board.

FPGA chip
SPARTAN 3E

Input channels 9-16

ADC2

Optical switches Control

Figure.3.3. Block diagram of data acquisition board
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Figure 3.4. Final manufactured FPGA based data acquisition board

The SPARTAN 3E FPGA has a USB 2 full-speed port for FPGA configuration and data transfers
to the laptop PC. Beside data acquisition, the FPGA is used to control the two optical switches of
4 x 1 and 1 x 9 for sequentially selecting one of the four wavelengths (740, 780, 808, 830nm) and
one of the 9 source positions on the hand-held probe. PMT detectors and parallel electronic
channels were used for parallel data acquisition
One of the other improvements in the third generation of our US-guided DOT system is
the increase in the number of detection channels from 10 to 14. Besides that, a new layout of the
electronics and optical components was designed to make the system as compact as possible
without sacrificing the system heat dissipation, robustness, and signal to noise ratio.
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Figure 3.5. shows the third prototype system dimensions (60 cm x 36 cm x 48 cm) and layouts.

Figure 3.5. The layout of the optimized third gen DOT system

Our hybrid probe used in previous clinical studies was not robust. A commercial US probe
was plugged into the open slot in the middle of the hybrid probe before each patient study and an
engineer operator had to hold the bundle of optical fibers and the US probe tightly together during
the study. Any significant bending of optical fibers during hand-held operation can produce bad
channel (either detector or source) data with lower signal due to light loss. Often, we have had to
manually remove these data during off-line processing. For the improved prototype, we use the
following design to improve the hybrid probe for robust and user-friendly operation. As shown in
Figure 3.6 (a), the US transducer will be inserted into the central slot of the probe base and firmly
locked to the probe base by two spring plungers which push the transducer down at its shoulder.
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After US transducer is connected, the probe cover which is used to cover and protect the optical
fibers and US transducer can lock in with the probe. The final probe will be free of hand and fiber
contact and easy to hold and operate as shown in Figure 3.6. (b).

(b)

(a)

Figure 3.6. (a) The improved hybrid probe design; (b) Probe cover and probe.

The intralipid phantom data were collected using the improved NIR system. Figure 3.7(a) shows
the amplitude vs. source-detector distance at 830nm, where amplitude is plotted in log(r2*I(r)).
The amplitude shows good linearity, and the dynamic range of system can reach to 60 dB. Figure
3.7. (b) shows the phase vs. source-detector distance.
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Figure 3.7. Intralipid phantom experiment data from the improved NIR system. (a) log(r2*I(r)) vs. sourcedetector distance; (b) Phase vs. source-detector distance

Figure 3.8 shows the block diagram of the optimized US-Guided NIR DOT system. Besides using
a faster FPGA based data acquisition, by optimizing electronic components we were able increase
number of detection channels from 10 to 14 in this new prototype. A custom made optical
decoupling board have been designed to decouple any noise transfer between source and detector
boxes and increase signal to noise ratio.
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7.5

Figure. 3.8. Block diagram of the third generation of the ultrasound guided DOT system.

After described optimization steps, three prototypes of the third-gen ultrasound guided DOT
system were developed and moved to three different hospitals for clinical studies.
Figure 3.9 shows a photograph of the upgraded NIR system used at the UCONN Health Center. A
commercial ultrasound transducer can be readily plugged into the hand-held probe for
simultaneous ultrasound and optical imaging.
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Figure 3.9. The upgraded NIR system currently used at the UCONN Health Center. The commercial
ultrasound transducer is readily plugged into the combined probe which houses all source and detector fibers
for light delivery and collection. The co-registered ultrasound images are captured by a video capture card
and are used to guide the light illumination and optical imaging reconstruction.
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3.5. Clinical Results
To validate the performance of the developed system in monitoring patients undergoing
neoadjuvant chemotherapy, we have done a clinical study with three systems at three different
hospitals. The study had IRB approval for all three sites and all patients consented to their
participation. In this section, we are going to describe the clinical results obtained from the first
patient. The first patient entered the new trial in March 2014 was a 37 years old woman with an
invasive mammary carcinoma of mixed lobular and ductal features. The histological grade and
nuclear grade were 3, and mitotic counts per 10 field high magnification were 9 and the
Nottingham score was 8 out of 9. The receptor status was ER positive, PR positive and HER2
positive. The pre-treatment MRI image, co-registered ultrasound image, and the corresponding
DOT total hemoglobin map are given in Figure 3.10 (a-c).
The total hemoglobin map is obtained in 7 slices from left to right and top to bottom
corresponding to depths of 0.5 cm to 3.5 cm from the skin surface to the chest wall. Each slide is
given in x-y spatial dimensions of 9 x 9 cm. The largest diameter of the tumor measured from
MRI images was 3.6 cm, measured from US images was 2.5 cm. The total hemoglobin distribution
provides functional information of tumor angiogenesis distribution and also quantitative levels.
The tumor vascular distribution is mainly distributed at the periphery of the mass which is often
seen in aggressive high-grade tumors. Quantitatively, the tHb level measured from the average
maximum of several tHb images at the tumor site was 81.02 mol/L. The patient was treated with
dual HER2 blockade of trastuzumab and pertuzumab for six cycles of total 18 weeks. The posttreatment MRI image, US, and DOT total hemoglobin map are given in Figure 3.10 (d-f). There
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was no residual tumor seen in MRI images. The ultrasound image revealed a smaller mass which
can be identified by the metal clip and total hemoglobin map revealed no vascular contrast. The
final surgery report revealed a grossly identified mass of 5.5 cm at the location of 10-2 o’clock.
Microscopically there were scattered tumor cells of ductal and lobular features within the scar
tissue. The largest residual focus measured 1.25 mm. The Miller Payne grade was 4.
To assess the early changes during NAC, we have monitored the patient at day 2, day 8,
end of cycle 1, 2 and 3. Figure 3.11 shows five sets of co-registered US images and total
hemoglobin maps obtained at these time points and Figure 3.12 is the quantitative total hemoglobin
level calculated from average maximum tHb levels with the average taken from several tHb images
at the tumor site at each time point. It is interesting to note that at day 2, the periphery distribution
of total hemoglobin is similar to the pre-treatment pattern, however, 24% higher total hemoglobin
content was observed which may due to initial tumor vascular response to NAC treatment. At day
8, the total hemoglobin map has changed to more centralized distribution, but the level is still 12%
higher than that at the pre-treatment level. At the end of cycle 1, the total hemoglobin level
dropped to 73% of the pre-treatment level. At the end of cycles 2 and 3, the tHb is in the
background level with no vascular contrast.
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Figure 3.10. Patient with an invasive mammary carcinoma located at 2 o’clock position of her left breast.
Baseline or pre-treatment MRI image (a), ultrasound image (b) and total hemoglobin map (c). Total
hemoglobin map revealed periphery distribution which is often seen in aggressive carcinomas. Post-treatment
MRI image (d), ultrasound image (e), and total hemoglobin map (f). MRI indicated no residual tumor and
total hemoglobin map showed no vascular contrast. The total hemoglobin map is obtained in 7 slices from left
to right and top to bottom corresponding to depths of 0.5 cm to 3.5 cm from skin surface to chest wall. Each
slide is given in x-y spatial dimensions of 9 x 9 cm.
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Figure
3.11. Co-registered US images and total hemoglobin maps obtained at five time points. Day 2, 8 and cycle 1
US images are zoomed into the depth range of 0 to 4 cm while Cycle 2 and 3 US images are zoomed in to the
range of 0 to 2.5 cm to better visualize the tumor.
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Figure 3.12. Quantitative total hemoglobin level calculated from average maximum tHb levels with the
average taken from several tHb images at the tumor site at each time point.

3.6. Summary
In summary, we have designed and constructed an upgraded frequency domain diffuse optical
tomography system for robust and reliable clinical operation at multiple clinical sites. The probe
can be easily adapted to any commercial ultrasound probe and the system is compact in size. Three
prototypes of the system were developed and used in three different hospitals. The systems have
been used for assessing neoadjuvant chemotherapy response of breast cancer patients and the
results are presented in the following sections. The results of one patients has been presented here
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and it shows promising results in prediction of patient’s response to neoadjuvant chemotherapy as
early as first cycle of chemotherapy. These 3 systems in three hospitals have been continued to be
used for clinical studies and the results has been submitted to the journal of clinical cancer research.
The results presented in this chapter have been published in multiple journals and conference
proceeding as listed in the reference [8-11]
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4. Development of Fourthgen US-guided DOT
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4.1. Abstract
Based on the statistics from World Health Organization, breast cancer is the most common cancer
among women worldwide, claiming the lives of hundreds of thousands of women each year. Nearinfrared diffuse optical tomography (DOT) has demonstrated a great potential as an adjunct
modality for differentiation of malignant and benign breast lesions and for monitoring treatment
response in patients with locally advanced breast cancers. The path toward commercialization of
DOT techniques depends upon the improvement of robustness and user-friendliness of this
technique in hardware and software. In the past, our group has developed frequency domain
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prototype systems which were used in several clinical studies. In this study, we introduce our
recently developed US-guided DOT system which is being improved in terms of size, robustness,
and user-friendliness by several custom electronics and improved mechanical design. The new
system benefits from a new user interface with includes automated data selection, outlier removal,
and lesion boundary detection as well as a new calibration method based on the depth and size of
the lesion detected from the ultrasound image. With all these improvements, our new system is
more robust and accurate which is one step closer to commercialization and widespread use of this
technology in clinical settings. This system is aimed to be used by minimally trained user in the
clinical settings with robust performance. The system performance has been tested with several
phantom experiments and the results show decent accuracy in terms of reconstructed absorption
as well as strong sensitivity in terms of oxygen saturation. The system was moved to a hospital
and was used in a clinical study to monitor patients undergoing neoadjuvant chemotherapy and the
results are presented.

4.2. Introduction
Breast cancer is the most common cancer among women and is expected to account for 29% all
new cancer diagnoses in women in 2017. Based on the statistics from American cancer society,
there are around 2.8 million women with a history of breast cancer in the United States (US). This
number includes women currently being treated and women who have completed treatment. In
2017, 255,180 new cases of invasive breast cancer along with 63,410 new cases of non-invasive
breast cancer will be detected in US. Despite the decrease in death rates for breast cancer since
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1989, it is estimated that about 40,610 women in the U.S. will die in 2017 from breast cancer [1,2].
Treatment for many breast cancer patients starts with preoperative or neoadjuvant therapy, which
includes chemotherapy, targeted therapy or hormone therapy to shrink the size of the lesion and
control the growth of the tumor before breast surgery. Neoadjuvant chemotherapy and hormone
therapy drugs are mostly same as those used after surgery (adjuvant therapy) and can shrink a
larger tumor enough so that lumpectomy plus radiation therapy becomes an alternative option to
mastectomy. Patients are usually assessed during neoadjuvant therapy on response in case of tumor
progression [3].
Different imaging methods have been used for both detection and treatment monitoring of
breast cancer. Conventional imaging methods such as Mammography, ultrasound imaging (US),
and magnetic resonance imaging (MRI), are the most commonly used methods for breast cancer
diagnosis. Mammography as the most clinically used imaging modality for breast cancer screening
and diagnosis has relatively low sensitivity in early cancer diagnosis especially low sensitivity in
women with dense breasts [4]. US demonstrates robust results in detecting breast cancer with
comparable rate to mammography, but it still lacks sensitivity and specificity [5]. MRI, on the
other hand, shows a significantly higher sensitivity in breast cancer detection and diagnosis
compared to US and mammogram, but the high costs of MRI and low cancer detection rate in the
general screening population limits its applicability as a screening and monitoring tool [4]. In the
treatment phase of breast cancer, different modalities have been used to monitor the patient
response to the neo-adjuvant therapy, while a method which can provide accurate results at early
stages of treatment is yet to be found. On one hand, US and mammography, are two highly used
methods to monitor the response of patients to Neo-adjuvant therapy and they just show moderate
sensitivity in the assessment of tumor response. On the other hand, dynamic contrast-enhanced
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MRI and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed
tomography (PET/CT) can predict the presence of residual tumor after completion of each NAC
which could decrease the patient additional exposure to ineffective and toxic treatments [4-6].
Although these methods have shown the ability in early identification of nonresponses, their
equipment is bulky and expensive, and they require the injection of contrast agents which prevent
them from being used repeatedly for monitoring patients during treatment.
Near-infrared (NIR) diffuse optical tomography (DOT) is a noninvasive imaging technique
that uses near-infrared light to assess optical properties of tissue. Because of the minimal light
absorption of water at the near infra-red wavelength range (∼700 to 900 nm), the light will
penetrate sufficiently in tissue to acquire tomographic images. Besides the low absorption of water
at near infra-red wavelength range, this wavelength range is also sensitive to oxygenated and
deoxygenated hemoglobin (HbO2 and Hb) [7-8]. DOT has shown promising results in the initial
assessing breast cancer because of its sensitivity to oxygenated and deoxygenated hemoglobin.
Besides that, DOT also has demonstrated great potential in the assessment of tumor vasculature
response to neoadjuvant chemotherapy. DOT systems are usually portable, require no contrast
agents, and have relatively low cost. Although these characteristics of DOT systems should make
them an ideal alternative for currently used modality for breast cancer diagnosis and monitoring
in clinical settings, but the low spatial resolution and lesion location uncertainty caused by intense
light scattering in soft tissue limits the wide use of this technology in the clinical setting. To
overcome this lower spatial resolution and location uncertainty, several groups investigated the
complimentary use of DOT along with other conventional imaging techniques. Multiple groups
have investigated the use of DOT guided by mammogram, US, and MRI [9-11] and demonstrated
DOT as a promising complementary method to the existing imaging modalities. We have studied
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the feasibility of using US-guided NIR imaging technique for detecting breast cancer as well as
monitoring patients who were undergoing Neo-adjuvant chemotherapy [11,12].
In recent years, we have devoted a great deal of time to improve the robustness of the diffuse
optical tomography in terms of hardware and software [12-14]. In this paper, we are introducing
a robust and commercially designed ultrasound-guided diffuse optical tomography system which
is moving this technology one step further in the commercialization and wide use in clinical setting.
A finite element based calibration method has been introduced to improve the sensitivity of the
system at different depth and size. The depth and size information has been made available from
co-registered ultrasound images. The performance of the system was evaluated by solid and blood
phantoms for absorption, total hemoglobin, and oxygen saturation sensitivity. The system was then
moved to hospital and used in the clinical study for monitoring patient’s response to neoadjuvant
chemotherapy. The monitoring results of the first patient are presented in this paper.

4.3. Method
4.3.1. System Structure
The miniaturized frequency domain imaging system was designed in order to move the
ultrasound-guided diffuse optical tomography system one step closer to wide use in clinical setting.
This system benefits from miniaturized hardware design which reduces the size and improves the
robustness of the DOT system. The system has four laser diodes of wavelengths 730, 785, 808 and
830nm as sources to characterize the breast tissue within a near-Infra red range and provide
oxygenated, deoxygenated, and total hemoglobin concentration inside the breast tissue. These 4
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laser diodes were sequentially switched by 4 x 1 and 1 x 9 optical switches to 9 source positions
on the hand-held probe. The reflected light from each source location was received simultaneously
at 14 parallel detection fibers and passed with fiber bundles to 14 PMT detectors. This system uses
heterodyne detection channels, at which the light sources were modulated at 140.2MHz and the
detected signals were mixed with the 140 MHz reference signal. The output of the mixers at each
channel was further amplified and filtered at 20 kHz. Since we are guiding our DOT with
ultrasound, a commercial ultrasound array transducer was located in the middle of the probe to
estimate the approximate depth and size of the lesion. In order to make this system appropriate to
be used by physicians in the clinical setting, a commercial case has been designed system based
on hospital safety and standards. For the convenience of the physicians, a moveable arm has been
added to this system in order to accommodate the touchscreen laptop for controlling data
acquisition and processing.
Fig. 4.1. Shows the diagram of the miniaturized system along with the developed system
which is currently moved to the hospital for clinical studies.
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Figure 4.1. Block diagram of miniaturized diffuse optical tomography system

4.3.2. Hardware Miniaturization
In this section, we describe the specific hardware miniaturization and improvements in our new
system. This system benefits from a miniaturized custom-made laser diode driver which can
accommodate up to 6 laser diodes, a miniaturized custom-made detection circuit to reduce number
of unnecessary cables and reduce the size and cost of the detection circuit, and a robust hand-held
probe which would enable us to connect the DOT system with commercial ultrasound system in
less than a minute in clinical setting. The details of hardware miniaturization processes are
described in the following subsections.

4.3.2.1.

Laser Diode Driver and Cooling

The DOT system has two main blocks as source and detector subsystems. One of the key
contributing factors in the size of the DOT system in the source subsystem is the light source, its
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associated current driver, frequency modulation blocks, and the cooling system. To miniaturize
the laser diode drivers, a custom-made board is designed in order to reduce the bulkiness and cost
of light source drivers. In our earlier prototypes, we were using 4 Thorlab’s current driver boards
which were running each laser diodes. This units were not only costly, they would increase the
total size of the source subsystem as we had to mount 4 of them inside the source subsystem. In
our new system, we have designed a single laser diode board which can accommodate up to 6 laser
diodes of type A and C. This module can provide a stable feedback controlled DC current for up
to 200 mA for each laser diode. Since we are modulating our light sources, this module has 6 build
in bias-tee and a RF input to modulate laser diodes with different RF frequencies. In our system,
all 4 light sources have been modulated at 140.02 MHz, which provide 4 frequency modulated
light sources at 4 different wavelengths. The other two laser diode driver ports are not used in our
current prototype since we are only using 4 wavelengths. Currently we are using four wavelengths
of 730, 785, 808 and 830 nm in NIR range which are sensitive to oxy and deoxy hemoglobin. The
output of the lasers is multiplexed via two optical switches from Piezojena co to 9 different
positions and the light is delivered to the tissue with 9 optical fibers through our hand-held probe.
Besides the laser diode current driver, we have tried to reduce the size of our laser diodes cooling
by using pigtailed laser diodes with thermal block from OZ Optics (LDPC-T3). The LDPC-T3
laser diode assembly has a flat metal surface on the back to attach a thermoelectric cooler (TEC).
The LDPC-T3 laser diode assembly has a built-in 10 kΩ NTC type thermistor sensor which
provides feedback for TEC cooler controller. The TCM1000T TEC control module from Thorlabs
has been used to control current TEC cooler through a Thermal Electric Cooler. The module is
designed to maintain temperature based on feedback provided from a 10 kΩ NTC type thermistor
sensor. Temperature is set and monitored using a scaled voltage based on the thermistor resistance
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for a given temperature, and is available at test points referenced to system ground. In this system
the TEC drivers have been adjusted to keep the all 4 laser diodes below room temperature at 15
degrees Celsius.

Heat Sink
TEC Cooler
Cooling Current

Thermistor 2

TCM 1000
Temperature
controller

Temp Feedback

Thermistor 1
LDPC-T3 Laser Diode

V Set

Figure 4.2. Thermal block laser diodes and it’s cooling system for forth-Gen DOT

4.3.2.2.

Miniaturized Detection Board

A custom-made miniaturized detection circuit is designed in order to miniaturize the system in the
detection subsystem. As this system uses a heterodyne detection system with two very high
frequency (140MHz and 140.02 MHz), the design need to be robust and precise to prevent any
high increase in frequency interference and baseline noise. Different scenarios have been tested to
miniaturize the detection circuit and finally we were able to successfully combine frequency mixer,
second stage amplifier and the band pass filter together in one miniaturized board to reduce the
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size of the detection channel. A gain adjustable amplifier is designed for this miniaturized detection
circuit to provide more freedom in the dynamic range of the system. In the current prototype the
gains for all 14 channels have been set to 55db. Besides that, a custom-made 20kHz band pass
filter has been designed to replace the expensive commercial band-pass filter with similar
performance in terms of baseline noise and filtering quality.

4.3.2.3.

PMT Control with DAC

In the third gen US-guided DOT I described the use of the FPGA based data acquisition board.
The miniaturized DAQ can accommodate up to 16 detection channels with two 8 channel A/D
chip. THE FPGA passes the converted digital signals to a laptop computer through USB port.
Besides data acquisition, this board is responsible for controlling the optical switches sequence. In
the new modification on the FPGA based data acquisition board, a port is dedicated to control the
sensitivity of the photon multiplier tubes.

4.3.3. Light Delivery and Probe Design
The system has two optical switches which sequentially multiplex the light of 4 laser diodes to 9
source fibers. These fibers then deliver the light into 9 source positions on our hand-held probe.
Both optical switches are controlled by the DAQ board and are synchronized with the data
acquisition. This light is then shined into tissue and the detected signals in the reflection geometry
was collected at 14 detection location on our probe. The detected light at each detection position
is then passed to the 14 parallel detection channels.
The ultrasound probe was located in the center of the probe to localize the lesion. In order
to use PMT detectors in their maximum dynamic range and prevent the saturation, the very short
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source- detector distances have been avoided in the system. The 9 sources are located in one side
of the probe and the 14 detectors are located on the other half of the probe. Fig. 4.3 shows the
distribution of source and detectors in the combined probe.

Figure 4.3. Combined diffuse optical tomography and ultrasound probe

4.3.4. Software Improvement
Improvements in robustness and user-friendliness of the software for diffuse optical tomography
is one of the important steps to move this technology toward wide use in clinical setting. Our
recent progress on reducing user interaction via automated calibration, outlier removal, data
selection and lesion boundary detection showed significant improvement in robustness and userfriendliness of the ultrasound-guided DOT. To move this technique one step closer to wide use
in the clinical setting, the presented prototype benefits from a graphical user interface with builtin automated data selection, outlier removal, lesion boundary detection from ultrasound image
and image reconstruction.
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4.4. Phantom Experiments
Multiple phantom experiments have been designed to evaluate the performance the system. In
the first sets of experiments, the sensitivity of the system to differentiating high contrast and low
contrast phantoms has been tested. Two sets of solid phantoms with absorption of 0.12 and 0.23
cm-1 and same scattering coefficient set at 7-8 cm-1 has been used. To evaluate the sensitivity of
the system to different size of phantoms, the system has been tested with three different size
(radius of 0.5, 1 and 1.5 cm) of each high contrast and low contrast phantoms. The phantoms
were placed in intralipid solution with absorption of 0.02cm-1 and scattering of 7-8 cm-1. The
Phantoms have been tested at different depths and below table shows the maximum
reconstructed absorption for each of them.

Table 4.1. Maximum reconstructed absorption map for high contrast and low contrast phantoms.
phantom

radius

absorption

SHC

0.5 cm

0.23 cm-1

SLC

0.5 cm

0.11 cm-1

MHC

1 cm

0.23 cm-1

MLC

1 cm

0.11 cm-1

LHC

1.5 cm

0.23 cm-1

LLC

1.5 cm

0.11 cm-1
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Table 4.2. Maximum reconstructed absorption map for high contrast and low contrast phantoms.
phantom

SHC

SLC

MHC

MLC

LHC

LLC

1 cm

0.146

0.098

1.5 cm

0.214

0.111

0.152

0.08

2 cm

0.246

0.083

0.206

0.077

0.148

0.08

2.5 cm

0.157

0.059

0.253

0.098

0.197

0.079

3 cm

0.091

0.052

0.227

0.084

0.25

0.09

3.5 cm

0.077

0.049

0.208

0.078

0.211

0.097

center depth

Figure 4.4 shows the stability of the system over time. The experiments have been repeated for 5
days and the results shows strong stability in the reconstructed absorption over time. The small
fluctuation of the reconstructed absorption value is related to the experimental errors, including
minor error in adjusting the phantom at exact depth of 2 cm.
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Maximum Reconstructed Absorption (cm-1)

730 nm
785 nm
808 nm
830 nm

0.3

0.25

0.2

0.15

0.1

0.05

0
Day 1

Day 2

Day 3
Experiment Time

Day 4

Day 5

Figure 4.4. Maximum reconstructed absorption for small high contrast phantom at depth of 2cm on different
dates. The reconstructed values at 730,785, 808 and 830nm are presented. The green dashed line represents
the actual absorption of the phantom.

For later phantom experiment, as Instrumentation Laboratory provides standard Hb
solution with the total hemoglobin (tHb) concentration similar to that of human and a known SO2
1, we propose to use this one (Multi-4, Level 2, Instrumentation Laboratory, MA) as the oxy-Hb
sample. The Multi-4, Level 2 product specification provided by Instrumentation Laboratory is
tHb=139 g/L, with HbO2 percentage equal to about 97%.

56

a

b

prob

0.8% intralipid
phanto

clay
Figure 4.5. (a) Glass ball (0.9 cm radius) filled with HbO2 solution and connected to holding fibers. (b) Sketch
of the testing experimental setup

Next, to evaluate the performance of the system in differentiating oxygenated and
deoxygenated hemoglobin, the experiment was designed using a hollow glass bulb filled with
oxygenated and deoxygenated hemoglobin.
The de-oxygenated hemoglobin (Hb) solution is prepared by adding Na2S2O4 solution
into the diluted oxygenated hemoglobin (HbO2). 0.05 g Na2S2O4 is solved in 0.5 mL PBS
solution (with 10 µL mixed solution corresponding to 1 mg Na2S2O4). We then add the Na2S2O4
solution into 3.5 mL HbO2 solution to prepare Hb solution. Solution preparation and mixing were
operated on top of the dry ice to keep the temperature at around 0 °C and slow down the speed of
de-oxygenated Hb reacting with O2. After sealing the glass ball, we incubated it at around 37 °C
for 6 min for the Na2S2O4 to work. We calibrated de-oxygenating process with a standard UV-
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Vis spectrometer (Varian Cary®, Agilent, US). For each ball and Hb solution, the DOT imaging
procedure was donein less than 10 minutes.
The images were reconstructed from measured data and the maximum reconstructed µa
were compared with the calibrated values with the spectrometer. We used the max reconstructed
µa to compute SO2. We analyzed the DOT measured SO2 of hemoglobin target at different
calibrated SO2 (~5-10% and ~97%).

Reconstructed a (/cm)

0.16
0.14
0.12
0.1
0.08

Hb
HbO2

0.06
0.04

730

780
808
Wavelength (nm)

830

Figure 4.6. Oxygenated and deoxygenated hemoglobin spectrum; a) reconstructed absorption based on 4
wavelength data with the DOT system. b) measured with spectrometer.

To evaluate the performance of the system in terms of sensitivity to oxygenated and deoxygenated
hemoglobin, 5 samples of oxygenated hemoglobin and 5 samples of deoxygenated hemoglobin
has been prepared separately in different dates and each sample was measured with the
spectrometer and then imaged with the ultrasound-guided DOT system. Table 4 demonstrates the
calibrated SO2 level for all 10 samples (5 oxygenated, 5 deoxygenated) with spectrometer along
with reconstructed SO2 level by using the ultrasound guided DOT system.
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Table 4.4. Reconstructed oxygen saturation of 100% oxygenated oxyhemoglobin and 0% deoxygenated
hemoglobin calculated with spectrometer as gold standard and DOT system for 5 different samples.
HBO2
Spectrometer
SAMPLE 1
SAMPLE 2
SAMPLE 3
SAMPLE 4
SAMPLE 5

97.8%
97.5%
97.4%
96.7%
97.3%

HB

DOT system
100%
100%
98.2%
100%
94.9%

Spectrometer
6.6%
5.3%
13.4%
6.0%
4.3%

DOT system
7.0%
4.7%
5.9%
1.4%
22.0%

It can be seen that the DOT system is following the spectrometer results very closely with a slight
variation. Figure 4.7 shows the comparison of these 5 oxygenated and deoxygenated samples
calibrated value with the spectrometer and calculated value with DOT system.
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Figure 4.7. Oxygenated and deoxygenated hemoglobin calibrated with spectrometer and measured with DOT
system

4.5. Finite element calibration
In order to improve the accuracy of the reconstructed absorption and total hemoglobin
concentrations, and reduce the sensitivity of the reconstructed value for different depth and size of
the lesion, a finite element model of the breast has been developed in COMSOL Multiphysics
(COSMOL Inc, Burlington, MA 01803). The model mimic the breast tissue in ultrasound guided
imaging technique as a 10cm cylinder with background optical properties of μa =0.02 cm-1 and
μs’=7cm-1 similar to the average normal breast. The model includes a spherical lesion with
different sizes and depth to mimic the lesion inside the breast. Figure 10 shows the finite element
model of the breast which has been used in this study.
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Figure 4.8. Finite element based cylindrical model of breast using COMSOL.

Since the ultrasound image provides the approximate depth and size of the lesions, we decided to
use this information in a finite element model to further calibrate our reconstructed absorption
maps. The model has been used to simulate the forward data for multiple lesions with different
sizes at different depth.
Using this model, we have reconstructed multiple lesions with different optical properties
and size at different depths. By comparing the average of maximum reconstructed absorption of
each lesion and average of the actual absorption of the lesions, a generalized calibration factor has
been calculated for each lesion size and depth. Then by using the depth and size information from
the ultrasound images we were able to calibrate the reconstructed absorption map for each lesion.
Table 5 shows the maximum reconstructed absorption by using the forward data provided by finite
element model. In order to decouple the effect of different absorption on the compensation factors,
for each radius of lesion at each depth, a range of absorption starting at 0.08 cm-1 up to 0.24 cm1 have been simulated.
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Table 4.5. Maximum reconstructed absorption for different lesions with absorption ranging from 0.08-0.24
cm-1 at different depths.

Lesion radius: 0.5 cm

Depth\mua

0.08 cm-1

0.12 cm-1

0.16 cm-1

0.20 cm-1

0.24 cm-1

1cm

0.0554

0.0837

0.1093

0.1324

0.1532

1.5cm

0.0711

0.1105

0.1474

0.1817

0.2133

2cm

0.0772

0.1209

0.1614

0.1988

0.2333

2.5cm

0.0622

0.096

0.1266

0.1544

0.1796

3cm

0.0373

0.0559

0.0729

0.0881

0.1016

3.5 cm

0.0337

0.0537

0.0719

0.0884

0.1034

Lesion radius: 1 cm
Depth\mua

0.08 cm-1

0.12 cm-1

0.16 cm-1

0.20 cm-1

0.24 cm-1

1.5cm

0.0754

0.1116

0.1395

0.1607

0.177

2cm

0.0958

0.1443

0.183

0.2138

0.2385

2.5cm

0.0921

0.1355

0.1703

0.1983

0.2211

3cm

0.0845

0.1218

0.1513

0.1751

0.1947

3.5cm

0.0884

0.1237

0.1514

0.1736

0.1917

Lesion radius: 1.5 cm
Depth\mua

0.08 cm-1

0.12 cm-1

0.16 cm-1

0.20 cm-1

0.24 cm-1

2cm

0.081

0.113

0.1331

0.1459

0.1544

2.5cm

0.0859

0.1219

0.1476

0.1662

0.1802

3cm

0.1036

0.1482

0.1806

0.2048

0.2234

3.5cm

0.095

0.1342

0.1631

0.1851

0.2023
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By using each reconstructed value, and comparing it to the real absorption in the model,
one calibration factor has been extracted. To eliminate the sensitivity of the compensation factor
to absorption of the lesion, the calibration factors was averaged over different optical absorptions.
As a result, one number was achieved as the calibration factor for each depth and size of the lesion.

Table 4.6. Calculated calibration factor for different size and depth of the lesion
Lesion Radius

Lesion Depth

0.5 cm

1 cm

1.5 cm

1cm

1.4981

1.5cm

1.1050

1.2045

2cm

1.0106

0.9139

1.2751

2.5cm

1.2928

0.9788

1.1399

3cm

2.2485

1.0998

0.9296

3.5cm

2.2786

1.0977

1.0260

The maximum reconstructed absorption of the high contrast and low contrast balls
presented in the section 3, has been calibrated using this calibrations factors. The results of the
calibrated maximum reconstructed absorption have been presented in table 4.7.
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Table 7. maximum reconstructed absorption for different size of high contrast and low contrast phantoms at
different depths after calibration with finite element model.
phantom

SHC

SLC

MHC

MLC

LHC

LLC

1 cm

0.178

0.135

1.5 cm

0.246

0.125

0.201

0.117

2 cm

0.332

0.139

0.205

0.072

0.136

0.088

2.5 cm

0.221

0.133

0.285

0.087

0.175

0.087

3 cm

0.277

0.108

0.293

0.139

0.229

0.112

3.5 cm

0.233

0.107

0.205

0.144

0.266

0.143

center depth

Figure 4.9. compares the average accuracy (%) of the maximum reconstructed absorption
for different solid high contrast and low contrast phantoms before and after finite element
calibration. The results show an increase in the average accuracy for different phantom sizes and
contrasts.
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Figure 4.9. Maximum reconstruction accuracy (%) for different phantoms before and after finite element
calibration

4.6. Summary
In summary, fourth generation of the DOT system has been presented in this chapter. This
generation of the system benefits from several improvements in terms of hardware and software
which make it more robust to be used in clinical setting. Besides that, we have worked alongside
a professional design company to improve the mechanical design and stability of the fourth
generation DOT system.
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The system was evaluated by intense phantom experiments and the results have been
presented and discussed here. Moreover, the new calibration method has been presented based on
the depth and size information of lesion acquired from the finite element simulation. This
calibration method uses readily provided information by ultrasound image in terms of depth and
size of the lesion and calibrate the reconstructed absorption based on that.
The results presented in this chapter are either published or under publication in multiple journal
and conference papers as listed in the reference [21,22].
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5. Reference Smoothing
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5.1. Abstract
Near infrared (NIR) diffuse optical tomography has demonstrated great potential in the initial
diagnosis of tumor and in the assessment of tumor vasculature response to neoadjuvant
chemotherapy. To reconstruct the absorption map of a breast lesion, perturbation is needed which
is the normalized difference between the measurements of lesion-side breast and contralateral
reference breast. However, the heterogeneity in the reference breast can produce unwanted
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perturbation which will result in distortion of the reconstructed target absorption map. This cahpter
introduces a filtering method to overcome the reference heterogeneity. This method corrects
affected source-detector measurements obtained from the reference side by using averages of
unaffected measurements. As a result, the filtered perturbation has decreased the effect of
heterogeneity on the reconstructed absorption maps. To evaluate the performance of this filtering
method, we have compared the reconstructed results with and without the filtering algorithm using
simulated heterogeneous reference with heterogeneous absorbers ranging from 0.05 to 0.20 cm-1
and heterogeneous scatters ranging from 10 to 20cm-1. The results show that the algorithm can
improve the maximum reconstructed target value up to 99% of the value with homogeneous
reference. In the worst case of high absorption heterogeneity in reference breast, the maximum
reconstructed value was around 30.85% of the true absorption without filtering correction and was
improved to 60.4% of the true absorption value, which is 95% of the reconstructed value when
using the homogeneous reference.

5.2. Introduction
Neoadjuvant chemotherapy (NAC) is a frequently used treatment to downstage the disease and
prepares patients with locally advanced breast cancers for surgery [1]. Different modalities have
been used to differentiate between patients who respond and who don't respond to NAC; while a
method which can provide accurate results at early stages of treatment is still under study. Physical
examination, ultrasound and mammography, conventionally are used to monitor the response of
patients to NAC and shown moderate results in the assessment of tumor response. In contrast to

71

conventional methods dynamic contrast enhanced MRI shows the ability in early identification of
nonresponders. This method can predict the presence of residual tumor after completion of each
NAC which could decrease the patient additional exposure to ineffective and toxic treatments [2].
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography
(PET/CT) have been reported to show good performance in excluding distant metastases prior to
neoadjuvant chemotherapy (NAC) treatment [3-5]. Besides these methods, near infrared (NIR)
diffuse optical tomography also has demonstrated great potential in assessment of tumor
vasculature response to neoadjuvant chemotherapy [3-5]. MRI and PET equipment are not only
bulky and expensive, but require the injection of contrast agents. These constraints prevent them
from being used repeatedly for monitoring patients during treatment. However, near infra-red
(NIR) systems are portable, require no contrast agents, and have lower cost which make them an
ideal alternative for repeated use in clinical settings.
Our group has studied the feasibility of using US-guided NIR imaging technique on patients
who were undergoing NAC. We assessed them at the pretreatment stage, at the end of every
treatment cycle, and before surgery. The system used in our study consists of four wavelength laser
diodes with 740, 780, 808, and 830 nm and ten channels detectors. The laser diodes are connected
to 4 by 1 switch and 1 by 9 switch. The source fibers and detector fibers are connected to a housing
probe with commercial US transducer located in the middle. Patients were scanned in a supine
position and multiple sets of ultrasound images and optical measurements with reflection geometry
were collected at the lesion location and at a contra-lateral region of the normal breast (reference
location). The results showed that the initial tumor Hb content was a strong predictor of final
pathologic response. Besides that, the tHb variation during early treatment cycles can be used to
predict final pathologic response [4, 5].
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Our experiments reveal that using a contralateral reference breast measurement to calculate
normalized perturbation could reduce the effect of different tissue properties in different patients
[6]. While using normalized perturbation can improve the consistency and reliability of the results
between different patients, it is highly dependent on the reference tissue, which is homogeneous
ideally. However, in clinical setting the reference tissue itself is not completely homogeneous
which can cause inaccuracy in calculating optical properties and tHb of the tumors. This chapter
is focused on evaluating the effect of heterogeneous reference breast on the optical properties and
shape of tumors.

5.3. Method and Model
In our phantom and clinical experiment procedure, two sets of measurements were collected from
lesion breast (lesion or target site) and contralateral normal breast (reference site) to calculate
normalized perturbation as shown below:

𝑈𝑠𝑐 (𝑖) =

𝐴𝑙 (𝑖)𝑒𝑥𝑝(𝜑𝑙 (𝑖))−𝐴𝑟 (𝑖)𝑒𝑥𝑝(𝜑𝑟 (𝑖))
𝐴𝑟 (𝑖)𝑒𝑥𝑝(𝜑𝑟 (𝑖))

(1)

where 𝐴𝑙 (𝑖),𝜑𝑙 (𝑖) were measured amplitude and phase for ith source-detector pair from lesion
breast while𝐴𝑟 (𝑖), 𝜑𝑟 (𝑖) were measured amplitude and phase for ith source-detector pair from
reference breast. Heterogeneity in the reference tissue can affect the reference measurements,
which can cause inaccuracy in normalized perturbation.

Finite-element based method in

COMSOL Multiphysics (COSMOL Inc, Burlington, MA 01803) was used to simulate the effect
of heterogeneous reference on the reconstructed NIR image. A 10cm cylinder was modeled as the
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scattered medium to mimic the breast tissue with optical properties of μa =0.02 cm-1 and μs’=7cm1. The ideal reference was homogeneous medium. To model the heterogeneity, a sphere with
different optical properties was placed inside the reference model. The position, size and optical
properties of heterogeneity were changed to mimic different scenario of heterogeneous reference
breasts. Same model was used for the lesion side without the heterogeneous target as shown in
Figure 1(a), but with a spherical lesion located at center in depth of 2cm with optical properties of
μa =0.2 cm-1 and μs’=7cm-1. The light was induced to the model from 9-point sources on the top
of the cylindrical model and the reflected light was collected at 14 different locations on top of the
cylinder to mimic the 9source positions and 14 detector channels in the hand-held probe. The
fluence distribution inside the medium when one source was on was shown in Figure 1(b).

Figure 5.1. Finite element based cylindrical model of breast using COMSOL.
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The simulated data at reference side and lesion sides was used to calculate normalized
perturbation based on formula (1). Optical properties of lesion inside breast were calculated by
using normalized perturbation and solving inverse problem.

The simulated data at reference side and lesion sides was used to calculate normalized
perturbation based on formula (1). Optical properties of lesion inside breast were calculated by
using normalized perturbation and solving inverse problem.
𝑈𝑠𝑐 = 𝑊 × 𝛿𝜇𝑎

(3)

[𝑚 × 1] = [𝑚 × 𝑛] × [𝑛 × 1]

To overcome effect of heterogeneity of modeled reference breast, a filtering method was
developed. Filtering method was focused on smoothing the reference breast measurements toward
homogeneous breast tissue measurements. Two different approaches developed to reduce the
effect of heterogeneity. First approach is based on smoothing the normalized perturbation directly
while second approach is based on smoothing the heterogeneous reference measurements only.

First approach (Perturbation Correction):
Find positive perturbation for each source detector pairs 𝑈𝑠𝑐 (𝑖) => 0
Calculate the average perturbation around that S-D distance by using other measurement data

∗ (𝑖)
{∀𝑖 ∈ [1, 𝑚] 𝑖𝑓 𝑈𝑠𝑐 (𝑖) > 0|𝑈𝑠𝑐
=

∑𝑘
𝑗=1 𝑈𝑠𝑐_𝑅 (𝑗)

where 𝑈𝑠𝑐_𝑅 are measurements from SD distance equal to i
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𝑘

}

(4)

Use corrected perturbation to solve the inverse problem and calculate absorption map.
∗
𝑈𝑠𝑐
= 𝑊 × 𝛿𝜇𝑎

(5)

[𝑚 × 1] = [𝑚 × 𝑛] × [𝑛 × 1]

Second approach (Reference Smoothing):
Find positive perturbation for each source detector pairs𝑈𝑠𝑐 (𝑖) => 0
Calculate the average reference measurement for S-Ds with similar distance.

{∀𝑖 ∈ [1, 𝑚] 𝑖𝑓 𝑈𝑠𝑐 (𝑖) > 0|𝑈𝑟 (𝑖) =

∑𝑘
𝑗=1 𝑈𝑟_𝑅 (𝑗)
𝑘

}

(6)

where 𝑈𝑟_𝑅 are measurements from SD distance equal to i

Smoothing reference based on approximated expected value calculated with other pairs in same
distance

∗
𝑈𝑠𝑐
(𝑖) =

𝑈𝑙 (𝑖)−𝑈𝑟∗ (𝑖)
𝑈𝑟∗ (𝑖)

(7)

Use smoothed reference to solve the inverse problem and calculate absorption map.
∗
𝑈𝑠𝑐
= 𝑊 × 𝛿𝜇𝑎

[𝑚 × 1] = [𝑚 × 𝑛] × [𝑛 × 1]
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(8)

5.4. Results
To evaluate the effect of heterogeneity in reference tissue on perturbation and reconstructed image
different sets of measurements from different reference and one set of measurement from
simulated lesion breast have been used to calculate perturbation and reconstruct the image. For the
sake of brevity, we illustrate the result of 3 cases here, but for all scenarios same trend is observed.
In first scenario perturbation have been calculated by using homogeneous reference with
homogeneous background optical properties of μa =0.02 cm-1 and μs’=7cm-1. In the second
scenario perturbation calculated by using heterogeneous reference with small heterogeneous ball
with radius of 0.5cm and optical properties of μa =0.02 cm-1 and μs’=7cm-1 in depth of 1 cm.
Finally, for third scenario an extreme case of heterogeneity have been considered. In this case
absorption coefficient of small ball in second scenario have been increased to μa =0.2 cm-1. Figure
5.2. (a) and (b) shows the normalized perturbation calculated with homogeneous reference while
Figure 5.2. (c) and (d) shows the real and imaginary parts of normalized perturbation calculated
with heterogeneous reference of second scenario and Figure 5.2 (e) and (f) shows the real and
imaginary parts of normalized perturbation calculated with heterogeneous reference of third
scenario. As shown in Figure 3, all the calculated perturbations are negative both in real and
imaginary parts when using homogeneous reference, while positive perturbation observed when
heterogeneous reference from second scenario have been used to calculate normalized
perturbations. Last row of figure 5.2 shows that by increasing the absorption heterogeneity in
reference tissue, the number and value of positive perturbation have been increased.

77

real part of perturbation

imaginary part of perturbation
0

-0.4
-0.6
0
0.5

Perturbation

Perturbation

-0.2

2
4
6
Sorce-Detector Distance

-0.05
-0.1
-0.15
-0.2
0

8

(a)

2
4
6
Sorce-Detector Distance

8

(b)

0.05
0
Perturbtion

Perturbation

0

0

-0.05
-0.1

-0.5
0

2
4
6
Source Detector distance

-0.15
0

8

(c)

0.2
Perturbation

Perturbation

0.5

0

2
4
6
Source-Detector Distance

8

imaginary part of perturbation

real part of perturbation

-0.5
0

2
4
6
Source Detecor distance

8

(d)

0.1

0
-0.1
0

2
4
6
Source-Detector Distance

8

(e) part of normalized perturbation a) & b) homogeneous
(f)
Figure 5.2. Real and imaginary
reference breast model,
c) &d) heterogeneous reference breast model in second scenario, e) &f) heterogeneous reference breast model
in third scenario.

The Effect of different references on the reconstructed image is illustrated in Figure 5.3.
Figure 5.3.a shows reconstructed image with normalized perturbation calculated from
homogeneous reference while 5.3.b and 5.3.c show reconstructed image heterogeneous references
described in scenario 2 and 3, respectively. Maximum reconstructed value by using homogeneous
reference was0.1271 cm-1. By using measurements from modeled reference in second scenario,
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maximum reconstructed value was changed to 13.06 cm-1 and with measurements from
heterogeneous reference in third scenario, maximum reconstructed value changed to 0.0617 cm1. It can be seen that by changing the amount of heterogeneity shape and maximum reconstructed
value of lesion has changed.
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Figure 5. 3. Effect of heterogeneity in the reference breast in the reconstructed image. a) Completely
homogeneous reference, b) Low absorption heterogeneity inside the reference, c) High absorption heterogeneity
inside the reference

Both perturbation correction and reference smoothing methods have been applied to the different
heterogeneous reference. After applying both of these approaches, in all the cases, the
reconstructed image was improved toward shape and value reconstructed by using homogeneous
reference. The result of both smoothing algorithms on the worst-case scenario with maximum
heterogeneity (third scenario) is discussed quantitatively.
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Figure 5.4. Reconstructed image based on a) Completely homogeneous reference, b) Heterogeneous reference
before correction, c) Heterogeneous reference after perturbation correction, d) Heterogeneous reference after
reference smoothing.

Figure 5.4 shows the reconstructed image with homogeneous reference, heterogeneous
reference without correction, heterogeneous reference with perturbation correction and
heterogeneous with reference smoothing. As shown in Figure 5.b, the shape and value of lesion by
using reference of third scenario differ dramatically from the reconstructed image by using
homogeneous reference in Figure 5.4.a. This heterogeneity caused maximum reconstructed value
to be less than 48.54% of the maximum reconstructed value with homogeneous reference. By
applying our reference smoothing and perturbation correction methods, we were able to improve
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it to 95.04% and 104.48% of reconstructed value with homogeneous reference, respectively.
Figure 5.c and 5.d shows the reconstructed image with heterogeneous reference of third scenario
with perturbation correction and reference smoothing, respectively.

The maximum reconstructed absorption with homogeneous reference, heterogeneous
reference of third scenario without correction, heterogeneous reference of third scenario with
perturbation correction and heterogeneous reference of third scenario with reference smoothing
are shown in table 5.1.

Table5.1. Maximum reconstructed absorption value with homogeneous, heterogeneous and heterogeneous
after applying perturbation correction and reference smoothing methods

µa

True value

Homogeneous
reference

Heterogeneous
reference

perturbation
correction

Reference
smoothing

0.2 cm-1

0.1271 cm-1

0.0617 cm-1

0.1328 cm-1

0.1208 cm-1

Although the effect of the heterogeneity inside the reference could not be completely
compensated, it could be reduced by applying these two methods. For example, in the case of high
heterogeneity inside the reference breast, the maximum reconstructed value shows 51.56% error
compared to the reconstructed value using homogeneous reference.

By applying the perturbation correction and reference smoothing methods, this error has
been reduced to 4.48% and 4.96%, respectively.
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Figure 5.5. Percentage of maximum reconstructed value with completely homogeneous reference (first column),
heterogeneous reference (second column), heterogeneous reference after perturbation correction (third
column) and heterogeneous reference after reference smoothing (fourth column).

This method has been used in multiple clinical cases with wavelength dependency due to
reference heterogeneity and the results have been improved significantly after using the reference
smoothing method. Below are the results of one malignant case before and after reference
smoothing. The results are showing clear increase in the consistency of the reconstructed image
across multiple wavelengths.
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Figure 5.6. Reconstructed image of a malignant case before and after reference smoothing method. The left
column represents the results of 740, 780, 808 and 830 nm before reference smoothing (a-d respectively) and
right column represents the results of 740, 780, 808 and 830 nm after reference smoothing (e-h respectively)
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5.5. Discussion
In this chapter the effect of the heterogeneity inside the reference breast on the perturbation and
reconstructed absorption map have been studied. The simulation indicates that by increasing the
heterogeneity inside the reference, the number and value of positive points in perturbation
increases dramatically. As demonstrated, this change in the perturbation will affect the
reconstructed absorption map in terms of maximum value, center and shape of the lesion inside
the target breast. The introduced smoothing methods show promising results to reduce the effect
of the heterogeneity in the reconstructed image. The application of the method on the clinical
results showed promising results in terms of improving the robustness of reconstructed absorption
map.

This simulation part of this method has been published in a proceeding paper at SPIE
conference and the completed method along with clinical cases will be further completed and
submitted separately [7].
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6. Automated Data PreProcessing
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6.1. Abstract
Imaging-guided near infrared diffuse optical tomography (DOT) has demonstrated a great
potential as an adjunct modality for differentiation of malignant and benign breast lesions and for
monitoring treatment response of breast cancers. However, diffused light measurements are
sensitive to artifacts caused by outliers and errors in measurements due to probe-tissue coupling,
patient and probe motions, and tissue heterogeneity.

In general, pre-processing of the

measurements is needed by experienced users to manually remove these outliers and therefore
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reduce imaging artifacts. An automated method of outlier removal, data selection, and filtering
for diffuse optical tomography is introduced in this chapter. This method consists of multiple steps
to first combine several datasets collected from the same patient at contralateral normal breast and
form a single robust reference dataset using statistical tests and linear fitting of the measurements.
The second step improves the perturbation measurements by filtering out outliers from the lesion
site measurements using model based analysis. The results of 20 malignant and benign cases show
similar performance between manual data processing and automated processing and improvement
in tissue characterization of malignant to benign ratio by about 27%.

6.2. Introduction
According to the American Cancer Society, breast cancer is estimated to be the most common type
of cancer among women with more than 246000 new cases and approximately 40,000 deaths
projected in the United States in 2016 [1]. Mammography, ultrasound (US) and magnetic
resonance imaging (MRI), are widely used to detect and diagnose breast lesions. Mammography
is the most clinically used imaging modality for breast cancer screening, but it suffers from
significant limitations such as relatively low sensitivity in early cancer diagnosis, reduced
sensitivity in women with dense breasts, and low specificity that results in a large number of
unnecessary biopsies [2]. A new study demonstrates comparable results for breast cancer detection
rate between US and mammography. However, US still lacks sensitivity and specificity with a
large number of false positive cases reported [3]. Although MRI has a higher sensitivity in breast
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cancer detection, the low cancer detection yields in the general screening population and high costs
of MRI prohibit its applicability as a screening tool [2].
Diffuse optical tomography (DOT) is a noninvasive functional imaging modality that
utilizes near-infrared (NIR) light to probe tissue optical properties. Minimal light absorption in the
NIR wavelength range allows for several centimeters of light penetration in soft tissue such as
breast and brain and facilitates probing lesions deep in the tissue. Image reconstruction is
performed using reflected or transmitted light at the tissue surface [4-7]. NIR diffuse optical
tomography has emerged as a promising modality to detect and monitor functional changes related
to blood flow and tumor angiogenesis. Using multi-wavelength data acquisition, it is possible to
quantify tissue characteristics such as oxygenated, deoxygenated, and total hemoglobin (HbO2,
HbR, and HbT) concentrations as well as hemoglobin oxygen saturation (SO2) and lipid and water
concentrations [8,9]. Clinical studies of female breasts have demonstrated higher HbT in the
malignant lesions compared to both healthy tissue and benign lesions [8,10,12,14,15].
High sensitivity and cost effectiveness of DOT make it an ideal alternative for conventional
breast imaging modalities. Currently DOT is not widely used in clinical settings mainly due to the
low spatial resolution and lesion location uncertainty caused by intense light scattering in soft
tissue. However, DOT guided by mammography, US, and MRI [10-13] have overcome lesion
location uncertainty and improved the light quantification accuracy, and have been demonstrated
as promising complementary methods to the existing imaging modalities. Ultrasound-guided DOT
system and technique has been developed by our group and clinical results have demonstrated its
potential in differentiating malignant and benign breast lesions and reducing the need for
unnecessary benign biopsies [10,15]. In this approach, DOT is used to characterize the US
detected lesions and to improve the diagnostic accuracy of US by providing complementary optical
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contrast. In a recent study, we have demonstrated that when US detection and diagnosis used
together with optical hemoglobin contrast, the sensitivity of breast cancer detection and diagnosis
has researched 96.6-100% [10].
The path toward commercialization of imaging guided DOT techniques depends upon the
improvement of robustness and user-friendliness of this technique in hardware and software.
Several groups have investigated various approaches to improve the robustness of the hardware,
system calibration, data selection, target localization, and image reconstruction [16-20]. Reducing
user interaction via automated processing of calibration and data selection is an important step
toward clinical applicability of DOT.
In US-guided DOT or other hand-held DOT operation, a hand-held probe is placed on top of a
patient’s breast while the patient is in a supine position [21]. Movements of patient or operator’s
hand could cause a bad coupling between the light guides and the breast which may result in some
outliers in measurements. In other imaging guided DOT approaches, the probe may be fixed,
however, the bad coupling between tissue and light guides can occur which may result in outlier
measurements. Additionally, tissue heterogeneity can cause measurement errors at some sourcedetector pairs. Recovered background and lesion optical properties highly depend on the boundary
measurements of light propagating through the tissue underneath and any errors in these
measurements could cause inaccuracy in fitted background and reconstructed lesion optical
properties [22,23]. In this study, we introduce an automated outlier removal, data selection, and
perturbation filtering method for imaging-guided DOT to improve its robustness in breast imaging.
This method utilizes multiple sets of reference measurements acquired at a normal contralateral
breast in one imaging session to produce a robust set of reference measurements. Then, the lesion
measurement set is subtracted and scaled by this robust reference to form the normalized
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perturbation of the scattered field. Next, the perturbation was filtered for outliers and measurement
errors based on analysis from simulations.

Finally, the filtered perturbation is used for

reconstruction of absorption maps and total hemoglobin distributions to characterize malignant
and benign breast masses. The method of combining multiple measurements to perform statistical
test for noise and outlier removal and saturation data rejection, can be applied to other methods of
imaging-guided DOT, such as mammogram or MRI guided diffuse optical tomography with some
modifications.

6.3. Dataset and System
6.3.1. Patients
US-guided DOT is used to characterize 10 malignant and 10 benign lesions of 20 patients. The
study protocol was approved by the local internal review board (IRB). Signed informed consent
was obtained from all patients and the study was compliant with the Health Insurance Portability
and Accountability Act. For each patient, US images and optical measurements were
simultaneously acquired before biopsy at the lesion site and at the normal contralateral breast of
the same quadrant as the lesion which is used as reference. Mammograms, US images before the
NIR scan were reviewed by attending radiologists and all contralateral measurements were taken
at normal areas based on the available information [10].
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6.3.2. System
The DOT system used in this study consisted of four laser diodes of wavelengths 740, 780, 808
and 830 nm. The outputs of the diodes were multiplexed by two optical switches to nine positions
and were then coupled to a hand-held probe through optical fibers. Ten optical light guides coupled
diffused light reflected from tissue to 10 photomultiplier tubes. The outputs of the laser diodes
were amplitude modulated at 140 MHz and the detector outputs were demodulated to 20 kHz. The
entire data acquisition took approximately 3 to 4 seconds, which was fast enough to repeat several
times during one imaging session and obtain multiple measurements from each patient at the lesion
site and the contralateral normal breast at the same quadrant as the lesion, referenced as reference
measurement in the following text. For each patient, we typically collect 4 to 6 sets of
measurements from the contralateral breast at slightly different locations. Each set consists of 3
consecutive measurements which takes around 4 to 5 seconds. The separation between each set of
measurements varies from few seconds to tens of seconds because of hand-held operation.
Therefore, a total 12 to 18 measurements may take about one to two minutes. A commercially
available US transducer located in the middle of the hand-held probe of 9 cm diameter was used
to acquire US images and optical source fibers and light guides distributed at the periphery were
used to collect the diffused light from tissue [10].

6.4. Methods
Fast data acquisition of US-guided DOT system allows the collection of several datasets during
one imaging session. The data contains multiple datasets from both lesion and contralateral
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reference breast. A novel automated method for outlier removal and data selection is introduced
to eliminate the effect of inaccurate measurements. The block diagram of the procedures is given
in Fig. (1).

k sets of reference measurements

MNR outlier removal
Data acquisition

Saturated and noise data removal

IRLS fitting with high residue removal

Compound reference

Lesion breast measurements

Perturbation filtering

Image reconstruction

Figure 6.1 Block diagram of the automated outlier removal and data selection method. In the block diagram
MNR stands for maximum normed residual and IRLS stands for iterative reweighted least square.
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Multiple sets of reference measurements were used to form a single high-quality dataset. First, an
outlier removal procedure is incorporated to eliminate the highly inaccurate measurements with a
criterion based on the distribution of data collected at each source-detector pair. Second, a piecelinear fitting is used to reject the source-detector pair measurements obtained from the saturated
PMTs. Third, an iterative fitting of residue of the remaining data is calculated to further eliminate
inaccurate measurements based on the linearity of fitted results of the reference measurements of
all source-detector pairs. Fourth, a least-square error method is used to form the most accurate
reference dataset from the remaining measurements. Finally, a perturbation filtering based on
analysis obtained from the semi-infinite analytical solution of light propagation in tissue [24] is
utilized to form accurate perturbation set that is more robust to outlier and inaccurate
measurements. The aforementioned steps are described in detail below.

6.4.1. Outlier Rejection in Reference Measurements
Each dataset contains measurements from s sources and d detectors with the total number of m=s×d
measurements. The system used in this study provides 90 source-detector measurements per
dataset. A total of k datasets of total k×s×d measurements collected at the reference site were used
for selecting a best reference dataset. In general, k is in the range of 12 to 18. Since we are using
a frequency domain DOT system, each dataset consists of amplitude and phase data. The
maximum normed residual (MNR) is a widely used statistical test to address the problem of outlier
rejection [25] that has shown outstanding performance in both linear and nonlinear data [26]. The
MNR test is based on the largest absolute deviation from the sample mean in units of the sample
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standard deviation. This test is applied to remove outliers for each source-detector pair of total k
datasets. The outlier measurement is expunged from each source-detector pair dataset based on the
following criterion. An upper critical value of the t-distribution with k−2 degrees of freedom is
calculated, and a threshold is obtained based on Eq. (1).

GThreshold (i) 

k 1

t2  2 k , k  2 (i)

k

k  2  t2  2 k , k  2 (i)

.

(1)

In this equation GThreshold(i) is the outlier threshold for ith source-detector pair, tα/(2k), k-2(i)
denotes the upper critical value of the t-distribution with k−2 degrees of freedom, and α represents
the level of significance which determines the strictness of outlier removal procedure. By
changing this value between 0 and 1, the total number of the outliers and the significance of these
outliers removed from the database have changed. To find the optimal value of α, the outlier
removal process is performed for different significance level ranging from 0.01 to 0.5 and the
optimal value is set to 0.05 based on visual examination of the removed outliers. This optimal
value is selected in a way that the test only removes the significant outlier data. A G value is
determined as an absolute deviation of the data point from mean value of the measurements and
normalized by standard deviation. The data point corresponding to maximum G value which has
absolute deviation higher than the threshold is considered as an outlier and removed from the
dataset. The test is iterated until no further outliers are detected beyond the threshold. This test is
done for both amplitude and phase measurements separately. The details of this method can be
found in [27,28]. If a data point in either amplitude or phase measurements is considered as an
outlier, both amplitude and phase measurements are removed from the datasets.
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6.4.2. Saturation and Noise Data Rejection
In addition to outliers in the reference measurements, detector saturation is another common
problem in DOT that can happen as a result of higher light intensity detected at a shorter source
detector distance. A semi-infinite analytic solution predicts that the logarithm of the detected
amplitude for each source-detector pair multiplied by square distance of that specific sourcedetector pair, referred as logarithmic amplitude, should linearly decrease with the source-detector
distance for homogeneous reference measurements. The phase measurement should increase
linearly with the source-detector distance. A piece-linear fitting method is implemented for the
amplitude measurements of all remaining source-detector pairs in the reference data after outlier
rejection. In general, three sections of shorter source-detector distance, mid-range, and longer
distance range were used. If a measured logarithmic amplitude at a shorter source-detector
distance does not follow the linear profile plotted as a function of the source-detector separation
in the mid and longer range, we can assume that the PMT is saturated at this detector distance. The
measurements that fit the linear profile are kept for further processing. Additionally, the phase data
corresponding to the saturated amplitude data are not reliable and are removed from both reference
and lesion datasets.
Besides the saturated measurements which usually happen for the source-detector pairs with
shorter distances, there are measurements of source-detector pairs with longer distances which are
dominated by the noise of the system and are not reliable. To improve the dataset, any
measurements of longer source detector pairs with amplitudes below the electronic noise of the
system are considered as noisy measurements and expunged from the data. Since the
corresponding phase data with amplitudes at noise level are not reliable and these data have also
removed from the data.
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6.4.3. Iterative Reweighted Least Square Fitting
The MNR test is based on each source detector measurements separately and it removes the
outliers at each source-detector pair. At this stage, all remaining datasets after MNR and saturation
data removal are inputted to an iterative reweighted least square (IRLS) method to obtain an
accurate linear fit with the minimum fitting residue for both log scaled amplitude and phase
measurements as functions of source and detector separation. This method has given great results
in different p-norm minimization problems ranging from compressive sensing to baseline
correction in industrial settings [29,30].
As shown in Eq. (2) IRLS iteratively minimizes the bi-square weighted residual in the
least-square sense [29]:
m

n1   w(i)n y(i)  f (i,  ) .
2

i 1

(2)

Here i is the index of the measurement, w is the bi-square weight function, y is the
measurement value, β includes slope and intercept of the line fitted to the data and f(i,β) is the
fitted measurement based on the current β . This method reduces the influence of large residuals
in the fitted reference parameters and improves the fitted results. After the fitting for both
logarithmic amplitude and phase is completed, the distance of each amplitude and phase
measurement from the corresponding value on the fitted line of same source-detector distance is
calculated. All the measurements with higher absolute residue compared to the threshold in either
amplitude or phase measurements are selected as non-accurate measurements and removed from
the dataset. The absolute residue threshold of 0.5 has been empirically selected for both amplitude
and phase based on trial and error from clinical data. Since the IRLS-based minimization is robust
and less sensitive to noise bursts, it improves the robustness of the dataset selection [30].
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6.4.4. Compounded Reference
Even though accurately fitted lines for both log scaled amplitude and phase are obtained from the
previous steps, there may still be more than one measurement for each remaining source-detector
separation. Now one amplitude and one phase measurement per source-detector pair need to be
selected to form a single robust reference dataset. Here, a least square method is utilized to select
the measurements with minimum distance from the center of the distribution of remaining
measurements for each source-detector pair. This processed is done separately on the remaining
amplitude and phase data. Therefore, a final reference dataset with high similarity to the fitted
slope and intercept of outlier removed combination of all the reference datasets is achieved. This
reference dataset consists of the selected amplitude and phase measurements for the remaining
source-detector pairs. This robust set of reference measurements is named as the compounded
reference and is less sensitive to outliers, PMT saturation and noise.
To visualize the effect of the proposed process, the amplitudes and phase profiles of one clinical
case before and after preprocessing, as well as the final compound reference have been illustrated
in Fig. 6.2. The preprocessing includes, outlier removal, saturation and noise rejection and iterative
reweighted fitting with higher residue removal.
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Fig. 6.2. Log scaled amplitude and phase profiles of reference datasets before (first column) and after
preprocessing (second column) as well as final compound reference (third column). Saturated source-detector
pairs have been marked with red rectangle in the amplitude part of the first column.

6.4.5. Perturbation filtering
The procedures described above provide a robust set of reference measurement. For reconstruction
of lesion absorption map at each wavelength, perturbation is calculated by subtracting the
compound reference from the lesion data as shown in Eq. (3), in which Al and Ar are amplitude
and φl and φr are phase of each source-detector pair obtained at the lesion and compound reference,
respectively.
U sc 
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(3)

The outliers may present in the perturbation data due to 1) measurements errors caused by
movements of patient or operator’s hand as well as bad coupling between the light guides and the
breast; and 2) heterogeneity of the background tissue and the lesion. Lesion measurements are
expected to be more heterogeneous than the reference measurements because the heterogeneity is
partially caused by the lesion and partially by the background tissue heterogeneity. Therefore,
outlier removal procedures applied to reference measurements cannot be implemented to the lesion
measurements. Instead, a filtering method is applied to the perturbation based on the constraints
imposed on the phase difference between the lesion data and the reference data given in Eq. (3).
These conditions are determined based on the predictions obtained from the semi-infinite
analytical solution derived from diffusion approximation [24, 31]. Simulations were performed
using different background optical properties for both reference and lesion breasts as well as
different optical properties for lesions of different sizes located at different depths [32]. The
simulations used the same probe geometry and the same number of the sources and detectors as
the experiments. Table 6.1 shows the range of the parameters used for simulations. The results
show that the maximum phase difference between lesion and reference measurements of all source
detector pairs for most scenarios listed in table 1 are in the range of few degrees. For a 4 cm larger
lesion of optical contrast of 10 times higher than the background, the maximum phase difference
is only 22 degrees. This implies that the maximum phase difference of none of the source detector
pairs can exceed 90 degrees even in extreme cases. This indicates that the cosine term in Eq. (3)
should always be positive. Therefore, the real part of the perturbation cannot be less than -1
assuming that the amplitude measured from lesion Al is smaller than that of the amplitude
measured at reference Ar due to a higher absorption of the lesion in general. Furthermore, the mean
and the standard deviation of the imaginary part of the perturbation are calculated. If the imaginary
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part of a data point is farther than three standard deviations from the mean, it is considered an
outlier. Any data points in the perturbation that do not meet these two criteria are rejected. This
step removes outliers in the perturbation likely caused by measurement errors rather than
heterogeneity of the lesion data.

Table 6.1. Range of parameters used for analytical model and obtained maximum phase delay.

Background μa

Background μ's

0.02 -0.08 (cm-1) 5 – 10 (cm-1)

Lesion Δμa

Lesion depth

0.05 – 0.2 (cm-1) 1.5- 3.5 (cm)

Lesion radius

0.5-2 (cm)

This normalized perturbation is used for reconstructing the absorption map at each wavelength.
The total hemoglobin map was calculated from the four wavelength absorption data. The dualzone mesh scheme is used for inversion [32]. Briefly, the imaging volume is segmented into two
regions consisting of the lesion and the background regions. These two regions are identified by
the co-registered ultrasound images. This method reduces the total number of voxels with
unknown optical properties by using smaller mesh size for lesion region and a larger coarse mesh
size for background. The conjugate gradient method is utilized for iterative optimization of the
inverse problem. Patient results are calculated from the selected data based on this automated
outlier removal and data selection procedures.
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6.5. Results
To quantify the effectiveness of the proposed method, the results obtained from manually selected
and processed dataset were compared with the results obtained from the automated data processing
method. The malignant versus benign classification was based on biopsy result which is the “gold”
standard in current clinical practice. The manual selection was performed by a trained user to
obtain the best outlier removal result. The absorption maps obtained at four optical wavelengths
of benign and malignant examples are shown in Figure 6.3 and 6.4, respectively. The effect of
outlier and bad measurements on the reconstructed image with no preprocessing is clearly seen
from the 740 nm image of first row in Fig. 6.4. Both manual and automated methods were able to
improve wavelength consistency by removing outlier measurements from the dataset. The
automated method provides similar reconstruction results as the manually processed ones with
only minor differences.
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Fig. 6.3. Reconstructed absorption maps of a benign breast lesion obtained at 740, 780, 808 and 830 nm with
no preprocessing (1st row), with manual data selection (2nd row) and automated data selection (3rd row). Each
slide is 9 cm by 9 cm reconstructed at the center depth of the lesion. Images from other depths were not shown.
Vertical bars are absorption in cm-1 unit.
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Fig. 6.4. Reconstructed absorption maps of a malignant breast lesion at 740, 780, 808 and 830 nm with no
preprocessing (1st row), with manual data selection (2nd row) and automated data selection (3rd row). Each slide
is 9 cm by 9 cm reconstructed at the center depth of the lesion. Images from other depths were not shown.
Vertical bars are absorption in cm-1 unit.

The corresponding ultrasound images and the calculated total hemoglobin maps obtained by both
manual and automatic methods along with calculated total hemoglobin maps with no outlier
removal and data selection are presented in Fig. (5) for the benign and malignant cases. The lower
reconstructed absorption at 740 nm of the malignant case with no data selection caused wavelength
inconsistency and reduced the calculated total hemoglobin concentration. It can be seen that both
manual and automated methods have improved wavelength consistency and better malignant to
benign separation by reducing the effect of saturated, noisy and outlier data. The HbT
concentrations are also comparable between manual and automated methods.
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Fig. 6.5. Ultrasound image (1st column) and total hemoglobin map calculated with no data selection (2nd
column), with manual data selection (3rd column) and automatic data selection (4th column) of the benign (top
row) and the malignant breast lesion (bottom row) reconstructed with automated data selection method. Each
slide is 9 cm by 9 cm and vertical bars are hemoglobin concentrations in uM unit.

To compare manual and automated methods statistically, both have applied to the datasets
collected from 20 patients (10 malignant and 10 benign). The maximum reconstructed absorption
coefficient with each method was calculated. The mean value and the standard deviation of the
maximum reconstructed absorption coefficient for malignant and benign groups along with the
ratio of the mean values are presented in Table 6.2. The proposed automated data selection and
outlier removal method shows slightly higher malignant to benign ratio of all wavelengths due to
improved data selection.
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Table 6.2. Comparison of maximum reconstructed absorption coefficients of malignant and benign groups
using manual and automated data selection method
Maximum reconstructed absorption with manual data selection (cm-1)
Malignant group

Benign group

Ratio

740 nm

0.22 (0.05)

0.11 (0.03)

2.02

780 nm

0.24 (0.05)

0.13 (0.04)

1.88

808 nm

0.24 (0.05)

0.14 (0.03)

1.74

830 nm

0.24 (0.04)

0.12 (0.04)

1.96

Maximum reconstructed absorption with automatic data selection (cm-1)
Malignant group

Benign group

Ratio

740 nm

0.209 (0.06)

0.10 (0.03)

2.06

780 nm

0.22 (0.06)

0.09 (0.03)

2.53

808 nm

0.23 (0.05)

0.09 (0.03)

2.57

830 nm

0.24 (0.06)

0.10 (0.03)

2.47

The total hemoglobin concentrations for all 20 patients are calculated using both manual and
automated data selection methods. Table 3 shows the comparison of the mean and the standard
deviation of the maximum total hemoglobin concentration reconstructed by both methods as well
as the ratio of the average HbT concentration between malignant and benign cases. Fig. (6) shows
the box plots of the reconstructed HbT concentrations of malignant and benign cases. The results
indicate a slight increase of the malignant to benign ratio of HbT from 2.01 to 2.55 by using the
automated data selection method.
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Table 6.3. Comparison of maximum reconstructed absorption coefficients of malignant and benign groups
using manual and automated data selection method
Maximum reconstructed total hemoglobin concentration (μM)
Benign group

Ratio

Manual Data selection

115.38 (20.90)

57.28 (12.38)

2.01

Automatic Data selection

112.31 (25.06)

43.97 (13.31)

2.55

Total Hemoglobin Concentration

Malignant group

160
140
120
100
80
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20
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Fig. 6.6. Comparison of maximum total hemoglobin concentration reconstructed with both manual and
automated data selection methods for 10 malignant and 10 benign cases. Vertical axis is the total hemoglobin
concentration in μmol/Liter.
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6.6. Discussion and Summary
In this chapter an automated pre-processing method for imaging-guided DOT is introduced. This
method combines multiple datasets obtained from a normal breast which is used as a reference and
implements outlier and saturation data removal, and linear fitting to form a robust compound set
of reference measurements. Because the reference site does not have lesions inside, the location
of the probe relative to the imaged area is not as critical as lesion site. Therefore, multiple reference
datasets obtained from slightly different positions can be combined and used as the inputs of the
automated compound reference selection method. On the other hand, in the affected breast, due to
the presence of the lesion, the described outlier removal and compound data selection method is
not appropriate. Instead, a perturbation filtering method, based on simulations, is introduced to
eliminate the outliers and inaccurate data due to measurement errors.
The clinical results using the automated compound reference selection method were
compared with the manually processed results. An experienced user performed the manual outlier
removal and data selection after the imaging session and the best manually selected datasets have
been used for the image reconstruction to compare with the automated method. Although the
results calculated by our experienced user shows high significance for malignant and benign
classification, the proposed automated compound outlier removal and data selection method
outperforms the experienced user without the need for user interactions. On average, an expert
need about 15 to 20 minutes to perform the outlier removal and data selection manually, while the
automated method takes about 20 seconds using a typical dual core computer of 2.3 to 2.8 GHz
speed. T-test is performed on the total hemoglobin results obtained from each method and the test
shows p-values of less than 0.001 in both cases which indicates strong statistical significance
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between malignant and benign groups. Although both methods provide strong statistical
significance between malignant and benign groups, but the ratio for malignant to benign has been
improved with the automated method. In particular, the ratio of malignant to benign lesions has
been increased from 2.01 using manual data selection to 2.55 using automated data selection
method with about 27% improvement.
Although our automated compound data selection method is introduced in the US-guided
DOT approach, it can be readily applied to other imaging guided DOT approaches. In general,
diffuse optical tomography relies on reference measurements either reference data from a normal
area of the same breast with lesions or a contralateral normal breast. The reference selected from
a normal area of the same patient is considered the best healthy control because each patient has
different background tissue optical properties depending on age, tissue composition, and
menopausal status as reported by several research groups in the past. Some groups used average
background tissue by excluding the tumor area in mammography guided or MRI guided diffuse
optical tomography [12]. Some groups used a localized area of healthy tissue in the lesion breast
[14] and some including our group used the mirror region in the contralateral breast [8, 10, 15].
Depending on the heterogeneity of the healthy tissue, the choice of reference area and the data
quality of the area impacts the level of tissue contrast. The proposed automated robust reference
selection method removes data outliers, rejects saturated and noise data, and performs a linear
fitting if a linear model is used such as approaches using hand-held probes where semi-infinite
boundary condition is applicable. Thus, the proposed automated reference selection method is
applicable to these approaches to improve the reference data quality, reduce data processing time.
This is an important step toward clinical translation and commercialization of diffuse optical
tomography techniques.
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In conclusion, an automated compound data selection method is introduced. This method
forms a compound set of measurements from multiple datasets and outperformed the manual
method in two different aspects. First, this method is able to eliminate the effect of inaccurate and
noisy measurements by combining multiple datasets and improves the differentiation between
malignant and benign cases. The results show improved differentiation between malignant and
benign lesions compared to the manual data selection. Second, this method makes outlier removal,
data selection, and processing automated by removing the need for experienced users to perform
the manual data selection and outlier removal. Utilizing the automated and compound data
selection method, the data processing speed is significantly improved, and the user dependency of
data processing is reduced. Future work includes automatic measurements of lesion boundaries in
US images and input the measurements into image reconstruction.
The results presented in this chapter was published in journal of biomedical optics express
and proceeding of OSA conference [32,33].
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7. Summary and Future
Works
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7.1. Summary
In this dissertation we have discussed the use of ultrasound-guided diffuse optical tomography
method to detect breast cancer and monitor patients undergoing neoadjuvant chemotherapy.
In the first chapter, we have briefly reviewed the history of medical imaging. The field first started
after discovery of X-rays and its application in imaging the tissue and bones. Several methods and
modalities for medical imaging has been developed during last century and they have found wide
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application in disease screening, diagnosis and treatment monitoring. We discussed that, while
each of the currently used conventional imaging, methods have their strength and drawbacks, the
need to develop a new imaging technique which could address current needs in medical
community and improve human health monitoring is being felt more than ever.
As described in chapter 2, One of the promising ideas for next gen medical imaging devices
are optical imaging. While several methods of optical imaging with different wavelength sub bands
are currently under investigation, we discussed the use of near-Infrared light in optical imaging.
The infrared light has multiple interesting characteristics such as good depth of penetration inside
the tissue and sensitivity to hemoglobin. In chapter 2, we specifically reviewed near-infrared
diffuse optical tomography method, followed by description of ultrasound-guided DOT to improve
the lesion localization and reconstruction accuracy. we have also discussed the use of diffuse
optical tomography in clinical setting for breast cancer detection.
In the third chapter, we discussed the development of the third generation of the ultrasoundguided diffuse optical tomography system and presented the results of clinical studies which have
been done with that system. we started by reviewing the older two generation of diffuse optical
tomography and then continued by the details of improvements in the third generation of the
ultrasound-guided DOT system. we discussed the new compact design, increase number of
detection channels, improved hand-held probe and improvements in the data acquisition and
design of the FPGA based data acquisition to reduce the system bulkiness and improve data
acquisition speed and robustness. Following the system development, we discussed the clinical
results obtained from one prototype of that system. The total hemoglobin monitoring for a breast
cancer patient undergoing neoadjuvant chemotherapy has been presented in that chapter. The
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results show the ability of the third generation of the ultrasound guided DOT system to monitor
patients undergoing neoadjuvant chemotherapy.
Chapter 4 was devoted to the development of the fourth generation of our ultrasound
guided diffuse optical tomography. The improvements in the system in terms of hardware and
software were discussed. Intensive phantom experiments have been designed and performed to
evaluate the performance of the fourth generation of the ultrasound guided DOT. The results show
strong ability of the system in reconstructing optical properties and total hemoglobin concentration
inside the tissue. Besides the system development an algorithm for calibration of the diffuse optical
tomography at different depth and sizes have been developed. The results show strong
improvement in the system sensitivity specially for the deeper targets.
Besides system robustness and stability, one of the main challenges in the clinical studies
of the using DOT for breast imaging is the effect of the heterogeneity in the reference
measurement. In chapter 5 we discussed the effect of reference heterogeneity on the reconstructed
absorption map. We introduced a smoothing method to reduce the effect of reference heterogeneity
and measurement inaccuracy in the reconstructed absorption map. The results show strong
improvement in the value and shape of reconstructed absorption map by use of this method.
In chapter 6, we introduced an automated algorithm for removing the need for expert user
to perform data selection and outlier removal. The discussed algorithm was using multiple
references and a perturbation filtering to eliminate the outliers in the measurements, make the
process of data preprocessing automated and form a robust reference measurement to improve the
accuracy of US-guided DOT. The results of a clinical data show strong improvements in the
differentiation of the malignant and benign lesion.
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The results of the developed systems and algorithms in the above in this dissertation was published
in multiple journal and conference proceedings as listed at the end of this chapter [1-15].

7.2. Future Works
By describing all the discussed topics in the previous 6 chapter we covered pretty much the steps
I took to move the ultrasound guided diffuse optical tomography one step closer to clinical use.
Although several improvements have been applied to the system development part and improve
the robustness of the DOT system, there are still several works remaining that one can continue
upon to increase the performance of the system. In terms of system development one of the first
steps can be taken is to increase number source wavelengths from four to 6 and incorporate
wavelengths in the range of 800-900 nm to probe additional chromophores inside the tissue,
including water and lipid.
In terms of software improvements, automated detection of the ultrasound boundaries is an
important step to make this process more robust and less user dependent. The process of automated
data selection can be extended to the different lesion measurements as well to improve the accuracy
of the system.
One of the main fields that one can improve is the use of ultrasound information in
differentiating malignant from benign lesions as well as monitoring patients undergoing
neoadjuvant chemotherapy. As we are currently only using the depth and size of the lesion
provided by the ultrasound images, looking into ultrasound signals would give us much more data.
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